US20200039945A1 - Compounds - Google Patents
Compounds Download PDFInfo
- Publication number
- US20200039945A1 US20200039945A1 US16/446,868 US201916446868A US2020039945A1 US 20200039945 A1 US20200039945 A1 US 20200039945A1 US 201916446868 A US201916446868 A US 201916446868A US 2020039945 A1 US2020039945 A1 US 2020039945A1
- Authority
- US
- United States
- Prior art keywords
- mmol
- mixture
- etoac
- lcms
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 282
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims description 169
- -1 cyano, hydroxy Chemical group 0.000 claims description 79
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 125000001153 fluoro group Chemical group F* 0.000 claims description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 41
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 29
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 13
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 12
- 125000001246 bromo group Chemical group Br* 0.000 claims description 7
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 464
- 239000000203 mixture Substances 0.000 description 358
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 236
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 231
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 178
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 172
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 166
- 239000000243 solution Substances 0.000 description 161
- 230000002829 reductive effect Effects 0.000 description 140
- 239000007787 solid Substances 0.000 description 134
- 238000005160 1H NMR spectroscopy Methods 0.000 description 131
- 238000004440 column chromatography Methods 0.000 description 124
- 239000007832 Na2SO4 Substances 0.000 description 112
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 112
- 229910052938 sodium sulfate Inorganic materials 0.000 description 112
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 70
- 239000000284 extract Substances 0.000 description 67
- 239000012267 brine Substances 0.000 description 62
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 62
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 55
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 50
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 49
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 47
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 45
- 229960001171 acetohydroxamic acid Drugs 0.000 description 45
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 44
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 40
- 239000000047 product Substances 0.000 description 40
- 125000001424 substituent group Chemical group 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- 239000012044 organic layer Substances 0.000 description 38
- 238000004809 thin layer chromatography Methods 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 33
- 238000001914 filtration Methods 0.000 description 33
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- 230000015572 biosynthetic process Effects 0.000 description 31
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 28
- 238000009472 formulation Methods 0.000 description 27
- 239000003208 petroleum Substances 0.000 description 26
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 25
- 150000001408 amides Chemical class 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 239000003112 inhibitor Substances 0.000 description 25
- 239000003921 oil Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- VHCODCZMAYFSHT-UHFFFAOYSA-N 5-ethyl-2-methoxybenzenesulfonyl chloride Chemical compound CCC1=CC=C(OC)C(S(Cl)(=O)=O)=C1 VHCODCZMAYFSHT-UHFFFAOYSA-N 0.000 description 24
- 101710203703 Peptidyl-lysine N-acetyltransferase YjaB Proteins 0.000 description 24
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 23
- 102100033071 Histone acetyltransferase KAT6A Human genes 0.000 description 23
- 101000944179 Homo sapiens Histone acetyltransferase KAT6A Proteins 0.000 description 23
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 23
- 239000010410 layer Substances 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 102100033070 Histone acetyltransferase KAT6B Human genes 0.000 description 21
- 229910000104 sodium hydride Inorganic materials 0.000 description 21
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- NLMVYUBGWZWUGB-UHFFFAOYSA-N 1,2-benzoxazol-3-amine Chemical compound C1=CC=C2C(N)=NOC2=C1 NLMVYUBGWZWUGB-UHFFFAOYSA-N 0.000 description 19
- 101710116149 Histone acetyltransferase KAT5 Proteins 0.000 description 19
- 125000005605 benzo group Chemical group 0.000 description 19
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 19
- KLVZDQNSNTUNGU-UHFFFAOYSA-N 2,6-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC(OC)=C1S(Cl)(=O)=O KLVZDQNSNTUNGU-UHFFFAOYSA-N 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 18
- 102100033068 Histone acetyltransferase KAT7 Human genes 0.000 description 17
- 101000944166 Homo sapiens Histone acetyltransferase KAT7 Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- 239000000377 silicon dioxide Substances 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- 229940124530 sulfonamide Drugs 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 16
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 15
- 229910052681 coesite Inorganic materials 0.000 description 14
- 229910052906 cristobalite Inorganic materials 0.000 description 14
- 239000007789 gas Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- 229910052682 stishovite Inorganic materials 0.000 description 14
- 229910052905 tridymite Inorganic materials 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 101000944174 Homo sapiens Histone acetyltransferase KAT6B Proteins 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 238000001959 radiotherapy Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 150000003456 sulfonamides Chemical class 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 235000019253 formic acid Nutrition 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical group C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 10
- IHRBIDHQEMTPAK-UHFFFAOYSA-N 4-chloro-1,2-benzoxazol-3-amine Chemical compound C1=CC(Cl)=C2C(N)=NOC2=C1 IHRBIDHQEMTPAK-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- YFNIGSJHKGKXEQ-UHFFFAOYSA-N 4-methoxy-1,2-benzoxazol-3-amine Chemical compound COC1=CC=CC2=C1C(N)=NO2 YFNIGSJHKGKXEQ-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 102000001805 Bromodomains Human genes 0.000 description 9
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 9
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000002480 mineral oil Substances 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- RCVMSHGRUGIUOD-UHFFFAOYSA-N 4-bromo-2-fluoro-6-methoxybenzonitrile Chemical compound COC1=CC(Br)=CC(F)=C1C#N RCVMSHGRUGIUOD-UHFFFAOYSA-N 0.000 description 8
- 108050009021 Bromodomains Proteins 0.000 description 8
- 101100019690 Homo sapiens KAT6B gene Proteins 0.000 description 8
- 230000021736 acetylation Effects 0.000 description 8
- 238000006640 acetylation reaction Methods 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 235000010446 mineral oil Nutrition 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 239000003039 volatile agent Substances 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 7
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 229910052723 transition metal Inorganic materials 0.000 description 7
- 150000003624 transition metals Chemical class 0.000 description 7
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010033040 Histones Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229910052805 deuterium Inorganic materials 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011369 resultant mixture Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- YDHCKXFPFBKZKF-UHFFFAOYSA-N 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile Chemical compound COc1cc(CO)cc(F)c1C#N YDHCKXFPFBKZKF-UHFFFAOYSA-N 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000002137 anti-vascular effect Effects 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000013456 study Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- CQWCDYBZNSNECQ-UHFFFAOYSA-N 1,3-dimethoxy-5-phenylbenzene Chemical group COC1=CC(OC)=CC(C=2C=CC=CC=2)=C1 CQWCDYBZNSNECQ-UHFFFAOYSA-N 0.000 description 4
- GNHVCDAPMWHFKG-UHFFFAOYSA-N 1-ethenyl-2,4-dimethoxybenzene Chemical compound COC1=CC=C(C=C)C(OC)=C1 GNHVCDAPMWHFKG-UHFFFAOYSA-N 0.000 description 4
- BCRRHGBLGOJJDH-UHFFFAOYSA-N 2,6-dimethoxy-3-phenylbenzenesulfonyl chloride Chemical compound COC1=C(C=CC(=C1S(=O)(=O)Cl)OC)C1=CC=CC=C1 BCRRHGBLGOJJDH-UHFFFAOYSA-N 0.000 description 4
- HWLUVGLJALRYAB-UHFFFAOYSA-N 2,6-dimethoxy-4-phenylbenzenesulfonyl chloride Chemical compound COC=1C=C(C=C(C=1S(=O)(=O)Cl)OC)C1=CC=CC=C1 HWLUVGLJALRYAB-UHFFFAOYSA-N 0.000 description 4
- GYOBZOBUOMDRRN-UHFFFAOYSA-N 2-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC=C1S(Cl)(=O)=O GYOBZOBUOMDRRN-UHFFFAOYSA-N 0.000 description 4
- KKNFEKITUMFHBI-UHFFFAOYSA-N 4-methoxy-6-(methoxymethyl)-1,2-benzoxazol-3-amine Chemical compound COC1=CC(=CC2=C1C(=NO2)N)COC KKNFEKITUMFHBI-UHFFFAOYSA-N 0.000 description 4
- CULLPWIGEXNOJD-UHFFFAOYSA-N 6-ethoxy-1,2-benzoxazol-3-amine Chemical compound CCOc1ccc2c(N)noc2c1 CULLPWIGEXNOJD-UHFFFAOYSA-N 0.000 description 4
- LEWWMCVROWPHOT-UHFFFAOYSA-N 7-ethoxy-1,2-benzoxazol-3-amine Chemical compound CCOc1cccc2c(N)noc12 LEWWMCVROWPHOT-UHFFFAOYSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 4
- 102100033069 Histone acetyltransferase KAT8 Human genes 0.000 description 4
- 101000944170 Homo sapiens Histone acetyltransferase KAT8 Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 229910006024 SO2Cl2 Inorganic materials 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- DPZNOMCNRMUKPS-UHFFFAOYSA-N resorcinol dimethyl ether Natural products COC1=CC=CC(OC)=C1 DPZNOMCNRMUKPS-UHFFFAOYSA-N 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
- FBPMXVZFVXPIJJ-UHFFFAOYSA-N 2,6-dimethoxy-3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound COC1=C(C(=CC=C1C(F)(F)F)OC)S(=O)(=O)Cl FBPMXVZFVXPIJJ-UHFFFAOYSA-N 0.000 description 3
- BDIHSSFYJYXWRV-UHFFFAOYSA-N 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(C#N)=C1F BDIHSSFYJYXWRV-UHFFFAOYSA-N 0.000 description 3
- CVJVSXKZGFQWJK-UHFFFAOYSA-N 2-fluoro-3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1F CVJVSXKZGFQWJK-UHFFFAOYSA-N 0.000 description 3
- DMJGKVYFBOCENL-UHFFFAOYSA-N 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C#N)C(F)=C1 DMJGKVYFBOCENL-UHFFFAOYSA-N 0.000 description 3
- DDLRNLRQRQZQET-UHFFFAOYSA-N 2-fluoro-6-methoxy-4-(2,2,2-trifluoroethoxymethyl)benzonitrile Chemical compound FC1=C(C#N)C(=CC(=C1)COCC(F)(F)F)OC DDLRNLRQRQZQET-UHFFFAOYSA-N 0.000 description 3
- UKXHDHDGVRSFNW-UHFFFAOYSA-N 2-methoxy-5-phenoxybenzenesulfonyl chloride Chemical compound COC1=C(C=C(OC2=CC=CC=C2)C=C1)S(Cl)(=O)=O UKXHDHDGVRSFNW-UHFFFAOYSA-N 0.000 description 3
- MBTSBVHGXVVXQW-UHFFFAOYSA-N 3-(3-amino-4-methoxy-1,2-benzoxazol-6-yl)phenol Chemical compound NC1=NOC2=C1C(=CC(=C2)C=1C=C(C=CC=1)O)OC MBTSBVHGXVVXQW-UHFFFAOYSA-N 0.000 description 3
- ABYNYTFGGHVVOK-UHFFFAOYSA-N 3-amino-1,2-benzoxazol-6-ol Chemical compound OC1=CC=C2C(N)=NOC2=C1 ABYNYTFGGHVVOK-UHFFFAOYSA-N 0.000 description 3
- UHPACMYLBFFXFM-UHFFFAOYSA-N 3-bromo-2-fluoro-6-methoxybenzonitrile Chemical compound COC1=CC=C(Br)C(F)=C1C#N UHPACMYLBFFXFM-UHFFFAOYSA-N 0.000 description 3
- KPEXZRFORIBRLJ-UHFFFAOYSA-N 3-ethyl-2,6-dimethoxybenzenesulfonic acid Chemical compound C(C)C=1C(=C(C(=CC=1)OC)S(=O)(=O)O)OC KPEXZRFORIBRLJ-UHFFFAOYSA-N 0.000 description 3
- ONEIGOGVJBKOGV-UHFFFAOYSA-N 3-ethyl-2,6-dimethoxybenzenesulfonyl chloride Chemical compound C(C)C=1C(=C(C(=CC=1)OC)S(=O)(=O)Cl)OC ONEIGOGVJBKOGV-UHFFFAOYSA-N 0.000 description 3
- KBCNRKZRISOYSR-UHFFFAOYSA-N 3-methoxy-5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride Chemical compound C1CCCC2=C1C=C(OC)C(S(Cl)(=O)=O)=C2 KBCNRKZRISOYSR-UHFFFAOYSA-N 0.000 description 3
- HEQPOVCFXDCSAJ-UHFFFAOYSA-N 4,6-dimethoxy-2,3-dihydro-1H-indene-5-sulfonyl chloride Chemical compound COC1=C2CCCC2=CC(=C1S(=O)(=O)Cl)OC HEQPOVCFXDCSAJ-UHFFFAOYSA-N 0.000 description 3
- MGMRAQPKVUCGMG-UHFFFAOYSA-N 4-(methoxymethyl)-1,2-benzoxazol-3-amine Chemical compound COCC1=CC=CC2=C1C(=NO2)N MGMRAQPKVUCGMG-UHFFFAOYSA-N 0.000 description 3
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 3
- AVBKISZUVMWQIA-UHFFFAOYSA-N 4-bromo-2-fluoro-5-methylbenzonitrile Chemical compound CC1=CC(C#N)=C(F)C=C1Br AVBKISZUVMWQIA-UHFFFAOYSA-N 0.000 description 3
- HGXWRDPQFZKOLZ-UHFFFAOYSA-N 4-bromo-2-fluorobenzonitrile Chemical compound FC1=CC(Br)=CC=C1C#N HGXWRDPQFZKOLZ-UHFFFAOYSA-N 0.000 description 3
- SLZIKPVLJWEOFJ-UHFFFAOYSA-N 4-ethoxy-1,2-benzoxazol-3-amine Chemical compound CCOC1=CC=CC2=C1C(N)=NO2 SLZIKPVLJWEOFJ-UHFFFAOYSA-N 0.000 description 3
- YMCXOHZKGNYIRT-UHFFFAOYSA-N 4-methoxy-6-(1-methoxyethyl)-1,2-benzoxazol-3-amine Chemical compound COC1=CC(=CC2=C1C(=NO2)N)C(C)OC YMCXOHZKGNYIRT-UHFFFAOYSA-N 0.000 description 3
- BIIHXLCRKKMHHD-UHFFFAOYSA-N 4-methoxy-7-phenyl-1,2-benzoxazol-3-amine Chemical compound COC1=CC=C(C2=C1C(=NO2)N)C1=CC=CC=C1 BIIHXLCRKKMHHD-UHFFFAOYSA-N 0.000 description 3
- BGMYWBQEKIMHGU-UHFFFAOYSA-N 5-bromo-1,2-benzoxazol-3-amine Chemical compound C1=C(Br)C=C2C(N)=NOC2=C1 BGMYWBQEKIMHGU-UHFFFAOYSA-N 0.000 description 3
- WUBKJPIYNZOHOF-UHFFFAOYSA-N 5-bromo-4-chloro-1,2-benzoxazol-3-amine Chemical compound BrC=1C=CC2=C(C(=NO2)N)C=1Cl WUBKJPIYNZOHOF-UHFFFAOYSA-N 0.000 description 3
- CUHBFQCMZMHUAZ-UHFFFAOYSA-N 5-bromo-4-methoxy-1,2-benzoxazol-3-amine Chemical compound BrC=1C=CC2=C(C(=NO2)N)C=1OC CUHBFQCMZMHUAZ-UHFFFAOYSA-N 0.000 description 3
- OQGCYVUAEXWVNE-UHFFFAOYSA-N 5-ethoxy-1,2-benzoxazol-3-amine Chemical compound CCOc1ccc2onc(N)c2c1 OQGCYVUAEXWVNE-UHFFFAOYSA-N 0.000 description 3
- KXUVDPSIZBQEBA-UHFFFAOYSA-N 5-ethyl-1-methyl-2-oxopyridine-3-sulfonyl chloride Chemical compound C(C)C=1C=C(C(N(C=1)C)=O)S(=O)(=O)Cl KXUVDPSIZBQEBA-UHFFFAOYSA-N 0.000 description 3
- GHZMPEYNUWHLHQ-UHFFFAOYSA-N 6-(methoxymethyl)-1,2-benzoxazol-3-amine Chemical compound COCc1ccc2c(N)noc2c1 GHZMPEYNUWHLHQ-UHFFFAOYSA-N 0.000 description 3
- IYDVUIPJYNITMC-UHFFFAOYSA-N 6-(methoxymethyl)-5-methyl-1,2-benzoxazol-3-amine Chemical compound COCC1=CC2=C(C(=NO2)N)C=C1C IYDVUIPJYNITMC-UHFFFAOYSA-N 0.000 description 3
- CNLHHYURQCSYLB-UHFFFAOYSA-N 6-bromo-1,2-benzoxazol-3-amine Chemical compound BrC1=CC=C2C(N)=NOC2=C1 CNLHHYURQCSYLB-UHFFFAOYSA-N 0.000 description 3
- SJOLEHYHMOBNIB-UHFFFAOYSA-N 6-methoxy-2,3-dihydro-1h-indene-5-sulfonyl chloride Chemical compound C1=C(S(Cl)(=O)=O)C(OC)=CC2=C1CCC2 SJOLEHYHMOBNIB-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 108091005625 BRD4 Proteins 0.000 description 3
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 101001046996 Homo sapiens Histone acetyltransferase KAT5 Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000004807 desolvation Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229960005419 nitrogen Drugs 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- NIUZVSQOXJIHBL-UHFFFAOYSA-N 1-bromo-2,4-dimethoxybenzene Chemical compound COC1=CC=C(Br)C(OC)=C1 NIUZVSQOXJIHBL-UHFFFAOYSA-N 0.000 description 2
- XRJYMHASJFSHRH-UHFFFAOYSA-N 1-ethyl-2,4-dimethoxybenzene Chemical compound CCC1=CC=C(OC)C=C1OC XRJYMHASJFSHRH-UHFFFAOYSA-N 0.000 description 2
- HDNRAPAFJLXKBV-UHFFFAOYSA-N 1-ethyl-4-methoxybenzene Chemical compound CCC1=CC=C(OC)C=C1 HDNRAPAFJLXKBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- IKLUEOPZYMFAQK-UHFFFAOYSA-N 2,4-dimethoxy-1-(trifluoromethyl)benzene Chemical compound COC1=CC=C(C(F)(F)F)C(OC)=C1 IKLUEOPZYMFAQK-UHFFFAOYSA-N 0.000 description 2
- HSKUIMHAKBYULE-UHFFFAOYSA-N 2,4-dimethoxy-1-phenylbenzene Chemical group COC1=CC(OC)=CC=C1C1=CC=CC=C1 HSKUIMHAKBYULE-UHFFFAOYSA-N 0.000 description 2
- RWQRMGCPYFBURB-UHFFFAOYSA-N 2-(bromomethyl)-6-chlorobenzonitrile Chemical compound ClC1=CC=CC(CBr)=C1C#N RWQRMGCPYFBURB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 2
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 2
- RCAQFMFKCMUPFI-UHFFFAOYSA-N 2-chloro-4-(3,5-dimethylpyrazol-1-yl)benzonitrile Chemical compound N1=C(C)C=C(C)N1C1=CC=C(C#N)C(Cl)=C1 RCAQFMFKCMUPFI-UHFFFAOYSA-N 0.000 description 2
- QEXGVMHGRLFPIN-UHFFFAOYSA-N 2-chloro-4-(triazol-2-yl)benzonitrile Chemical compound ClC1=C(C#N)C=CC(=C1)N1N=CC=N1 QEXGVMHGRLFPIN-UHFFFAOYSA-N 0.000 description 2
- PGKPNNMOFHNZJX-UHFFFAOYSA-N 2-chloro-4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C(Cl)=C1 PGKPNNMOFHNZJX-UHFFFAOYSA-N 0.000 description 2
- HMKIKFUHXWNIHM-UHFFFAOYSA-N 2-chloro-6-(methoxymethyl)benzonitrile Chemical compound COCC1=CC=CC(Cl)=C1C#N HMKIKFUHXWNIHM-UHFFFAOYSA-N 0.000 description 2
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 2
- HVAKERNUWAPZOR-UHFFFAOYSA-N 2-ethoxy-6-fluorobenzonitrile Chemical compound CCOC1=CC=CC(F)=C1C#N HVAKERNUWAPZOR-UHFFFAOYSA-N 0.000 description 2
- ZNBDHKYUVUUZSI-UHFFFAOYSA-N 2-fluoro-3-pyrimidin-2-ylbenzonitrile Chemical compound FC1=C(C#N)C=CC=C1C1=NC=CC=N1 ZNBDHKYUVUUZSI-UHFFFAOYSA-N 0.000 description 2
- QCGVTQNVQWPXQA-UHFFFAOYSA-N 2-fluoro-4-(1-hydroxyethyl)-6-methoxybenzonitrile Chemical compound FC1=C(C#N)C(=CC(=C1)C(C)O)OC QCGVTQNVQWPXQA-UHFFFAOYSA-N 0.000 description 2
- DUZIPTYSUQETTR-UHFFFAOYSA-N 2-fluoro-4-(3-hydroxyphenyl)-6-methoxybenzonitrile Chemical compound O(C1=C(C#N)C(F)=CC(C2=CC(O)=CC=C2)=C1)C DUZIPTYSUQETTR-UHFFFAOYSA-N 0.000 description 2
- DAHBQEGFMSLLMH-UHFFFAOYSA-N 2-fluoro-4-(hydroxymethyl)-5-methylbenzonitrile Chemical compound Cc1cc(C#N)c(F)cc1CO DAHBQEGFMSLLMH-UHFFFAOYSA-N 0.000 description 2
- JGHFNHVMBWFAGJ-UHFFFAOYSA-N 2-fluoro-4-(methoxymethyl)-5-methylbenzonitrile Chemical compound FC1=C(C#N)C=C(C(=C1)COC)C JGHFNHVMBWFAGJ-UHFFFAOYSA-N 0.000 description 2
- VFGXWMIHKUTIGO-UHFFFAOYSA-N 2-fluoro-4-(oxan-2-yloxy)benzonitrile Chemical compound C1=C(C#N)C(F)=CC(OC2OCCCC2)=C1 VFGXWMIHKUTIGO-UHFFFAOYSA-N 0.000 description 2
- PDIXHOXKFPTGOO-UHFFFAOYSA-N 2-fluoro-4-(triazol-1-yl)benzonitrile Chemical compound N1(C=CN=N1)C1=CC=C(C(F)=C1)C#N PDIXHOXKFPTGOO-UHFFFAOYSA-N 0.000 description 2
- QMVQCZURALJGBP-UHFFFAOYSA-N 2-fluoro-4-pyrazol-1-ylbenzonitrile Chemical compound C1=C(C#N)C(F)=CC(N2N=CC=C2)=C1 QMVQCZURALJGBP-UHFFFAOYSA-N 0.000 description 2
- NVHJLYVINACKFB-UHFFFAOYSA-N 2-fluoro-4-pyridin-2-ylbenzonitrile Chemical compound C1=C(C#N)C(F)=CC(C=2N=CC=CC=2)=C1 NVHJLYVINACKFB-UHFFFAOYSA-N 0.000 description 2
- WGCJETPJJRTGMP-UHFFFAOYSA-N 2-fluoro-4-pyrimidin-2-ylbenzonitrile Chemical compound C1=C(C#N)C(F)=CC(C=2N=CC=CN=2)=C1 WGCJETPJJRTGMP-UHFFFAOYSA-N 0.000 description 2
- HFLYBTRQFOKYHC-UHFFFAOYSA-N 2-fluoro-5-hydroxybenzonitrile Chemical compound OC1=CC=C(F)C(C#N)=C1 HFLYBTRQFOKYHC-UHFFFAOYSA-N 0.000 description 2
- VBZLRHYLNXWZIU-UHFFFAOYSA-N 2-fluoro-5-methoxybenzonitrile Chemical compound COC1=CC=C(F)C(C#N)=C1 VBZLRHYLNXWZIU-UHFFFAOYSA-N 0.000 description 2
- BCEXVECEWCKRLI-UHFFFAOYSA-N 2-fluoro-5-methyl-4-(1,3-oxazol-2-yl)benzonitrile Chemical compound FC1=C(C#N)C=C(C(=C1)C=1OC=CN=1)C BCEXVECEWCKRLI-UHFFFAOYSA-N 0.000 description 2
- OFCHKLACMXYUHP-UHFFFAOYSA-N 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile Chemical compound CC1=CC(C#N)=C(F)C=C1B1OC(C)(C)C(C)(C)O1 OFCHKLACMXYUHP-UHFFFAOYSA-N 0.000 description 2
- UHLUZNMWEOIVRR-UHFFFAOYSA-N 2-fluoro-5-methyl-4-pyridin-2-ylbenzonitrile Chemical compound FC1=C(C#N)C=C(C(=C1)C1=NC=CC=C1)C UHLUZNMWEOIVRR-UHFFFAOYSA-N 0.000 description 2
- CKTXLFBVFSYAKA-UHFFFAOYSA-N 2-fluoro-6-methoxy-3-(1-methylpyrazol-4-yl)benzonitrile Chemical compound FC1=C(C#N)C(=CC=C1C=1C=NN(C=1)C)OC CKTXLFBVFSYAKA-UHFFFAOYSA-N 0.000 description 2
- RBQLOFHYDNFTPZ-UHFFFAOYSA-N 2-fluoro-6-methoxy-3-phenylbenzonitrile Chemical compound FC1=C(C=CC(=C1C#N)OC)C1=CC=CC=C1 RBQLOFHYDNFTPZ-UHFFFAOYSA-N 0.000 description 2
- QYROYYYNPCHLDL-UHFFFAOYSA-N 2-fluoro-6-methoxy-4-(1,3-oxazol-2-yl)benzonitrile Chemical compound FC1=C(C#N)C(=CC(=C1)C=1OC=CN=1)OC QYROYYYNPCHLDL-UHFFFAOYSA-N 0.000 description 2
- SNPBUJNXTRAKPV-UHFFFAOYSA-N 2-fluoro-6-methoxy-4-(1-methoxyethyl)benzonitrile Chemical compound FC1=C(C#N)C(=CC(=C1)C(C)OC)OC SNPBUJNXTRAKPV-UHFFFAOYSA-N 0.000 description 2
- NDECHZVOQVSQLW-UHFFFAOYSA-N 2-fluoro-6-methoxy-4-(methoxymethyl)benzonitrile Chemical compound FC1=C(C#N)C(=CC(=C1)COC)OC NDECHZVOQVSQLW-UHFFFAOYSA-N 0.000 description 2
- NPNBPNLAKSDQCA-UHFFFAOYSA-N 2-fluoro-6-methoxy-4-phenylbenzonitrile Chemical compound FC1=C(C#N)C(OC)=CC(C=2C=CC=CC=2)=C1 NPNBPNLAKSDQCA-UHFFFAOYSA-N 0.000 description 2
- YMIGAFNIDPBXRW-UHFFFAOYSA-N 2-fluoro-6-methoxy-4-pyridin-2-ylbenzonitrile Chemical compound FC1=C(C#N)C(=CC(=C1)C1=NC=CC=C1)OC YMIGAFNIDPBXRW-UHFFFAOYSA-N 0.000 description 2
- FRNCUKMXDOBSNU-UHFFFAOYSA-N 2-methoxy-5-phenoxybenzenesulfonic acid Chemical compound COC1=C(C=C(C=C1)OC1=CC=CC=C1)S(=O)(=O)O FRNCUKMXDOBSNU-UHFFFAOYSA-N 0.000 description 2
- AJUBCDYTYLYQPG-UHFFFAOYSA-N 3-(cyclopropylmethoxy)-2-fluorobenzonitrile Chemical compound C1(CC1)COC=1C(=C(C#N)C=CC=1)F AJUBCDYTYLYQPG-UHFFFAOYSA-N 0.000 description 2
- MNOZHTZMMVEKLR-UHFFFAOYSA-N 3-amino-N-(2,2-dimethoxyethyl)-1,2-benzoxazole-6-carboxamide Chemical compound NC1=NOC2=C1C=CC(=C2)C(=O)NCC(OC)OC MNOZHTZMMVEKLR-UHFFFAOYSA-N 0.000 description 2
- ODUWWKCYNUBYRT-UHFFFAOYSA-N 3-bromo-2-chloro-6-fluorobenzonitrile Chemical compound FC1=CC=C(Br)C(Cl)=C1C#N ODUWWKCYNUBYRT-UHFFFAOYSA-N 0.000 description 2
- HUAHYBZBHGOZHJ-UHFFFAOYSA-N 3-bromo-2-fluoro-5-methylbenzamide Chemical compound CC1=CC(Br)=C(F)C(C(N)=O)=C1 HUAHYBZBHGOZHJ-UHFFFAOYSA-N 0.000 description 2
- JFAQBRSYTNDGBL-UHFFFAOYSA-N 3-bromo-2-fluoro-5-methylbenzoic acid Chemical compound CC1=CC(Br)=C(F)C(C(O)=O)=C1 JFAQBRSYTNDGBL-UHFFFAOYSA-N 0.000 description 2
- HHWSLVGBHIQKAW-UHFFFAOYSA-N 3-bromo-2-fluoro-5-methylbenzoyl chloride Chemical compound CC1=CC(Br)=C(F)C(C(Cl)=O)=C1 HHWSLVGBHIQKAW-UHFFFAOYSA-N 0.000 description 2
- AMKVZJOQZLIOSL-UHFFFAOYSA-N 3-bromo-2-fluorobenzonitrile Chemical compound FC1=C(Br)C=CC=C1C#N AMKVZJOQZLIOSL-UHFFFAOYSA-N 0.000 description 2
- GXXLFWVZJWQVPQ-UHFFFAOYSA-N 3-bromo-6-fluoro-2-methoxybenzamide Chemical compound COC1=C(Br)C=CC(F)=C1C(N)=O GXXLFWVZJWQVPQ-UHFFFAOYSA-N 0.000 description 2
- WRSPJCQSBRAYCE-UHFFFAOYSA-N 3-bromo-6-fluoro-2-methoxybenzoic acid Chemical compound COC1=C(Br)C=CC(F)=C1C(O)=O WRSPJCQSBRAYCE-UHFFFAOYSA-N 0.000 description 2
- OZUSRRAXOTZOSM-UHFFFAOYSA-N 3-bromo-6-fluoro-2-methoxybenzonitrile Chemical compound COC1=C(Br)C=CC(F)=C1C#N OZUSRRAXOTZOSM-UHFFFAOYSA-N 0.000 description 2
- NRUNOKNBZYDSTD-UHFFFAOYSA-N 3-ethoxy-2-fluorobenzonitrile Chemical compound CCOC1=CC=CC(C#N)=C1F NRUNOKNBZYDSTD-UHFFFAOYSA-N 0.000 description 2
- MOQGYMRQCJOIOT-UHFFFAOYSA-N 4,6-dimethoxy-2,3-dihydro-1h-indene Chemical compound COC1=CC(OC)=CC2=C1CCC2 MOQGYMRQCJOIOT-UHFFFAOYSA-N 0.000 description 2
- OUNCVTQWINHMFI-UHFFFAOYSA-N 4-(1-ethoxyethenyl)-2-fluoro-6-methoxybenzonitrile Chemical compound C(C)OC(=C)C1=CC(=C(C#N)C(=C1)OC)F OUNCVTQWINHMFI-UHFFFAOYSA-N 0.000 description 2
- UKUBMSGIMQDVNC-UHFFFAOYSA-N 4-(difluoromethoxy)-2,6-difluorobenzonitrile Chemical compound FC(F)OC1=CC(F)=C(C#N)C(F)=C1 UKUBMSGIMQDVNC-UHFFFAOYSA-N 0.000 description 2
- SVEGDMNIRMPOLW-UHFFFAOYSA-N 4-(ethoxymethyl)-2-fluoro-6-methoxybenzonitrile Chemical compound C(C)OCC1=CC(=C(C#N)C(=C1)OC)F SVEGDMNIRMPOLW-UHFFFAOYSA-N 0.000 description 2
- VVTGSZRVMRVIEH-UHFFFAOYSA-N 4-(trifluoromethyl)-1,2-benzoxazol-3-amine Chemical compound C1=CC(C(F)(F)F)=C2C(N)=NOC2=C1 VVTGSZRVMRVIEH-UHFFFAOYSA-N 0.000 description 2
- MYJYCXWBFMNDGN-UHFFFAOYSA-N 4-acetyl-2-fluoro-6-methoxybenzonitrile Chemical compound COc1cc(cc(F)c1C#N)C(C)=O MYJYCXWBFMNDGN-UHFFFAOYSA-N 0.000 description 2
- LGKPLZRCHZYXML-UHFFFAOYSA-N 4-azido-2-fluorobenzonitrile Chemical compound C(#N)C1=C(C=C(C=C1)N=[N+]=[N-])F LGKPLZRCHZYXML-UHFFFAOYSA-N 0.000 description 2
- SYCUVFGUHBRMHZ-UHFFFAOYSA-N 4-bromo-1,2-benzoxazol-3-amine Chemical compound C1=CC(Br)=C2C(N)=NOC2=C1 SYCUVFGUHBRMHZ-UHFFFAOYSA-N 0.000 description 2
- QPPCLNMOYHCXMS-UHFFFAOYSA-N 4-bromo-2-methoxybenzenesulfonyl chloride Chemical compound COC1=CC(Br)=CC=C1S(Cl)(=O)=O QPPCLNMOYHCXMS-UHFFFAOYSA-N 0.000 description 2
- DPNNFOMJLUZLFS-UHFFFAOYSA-N 4-chloro-5-methyl-1,2-benzoxazol-3-amine Chemical compound ClC1=C(C=CC2=C1C(=NO2)N)C DPNNFOMJLUZLFS-UHFFFAOYSA-N 0.000 description 2
- UCMPFBWQSCDQMY-UHFFFAOYSA-N 4-cyano-3-fluorobenzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=CC=C1C#N UCMPFBWQSCDQMY-UHFFFAOYSA-N 0.000 description 2
- FCTRBCMNBYFRQU-UHFFFAOYSA-N 4-cyano-N-(2,2-dimethoxyethyl)-3-fluorobenzamide Chemical compound C(#N)C1=C(C=C(C(=O)NCC(OC)OC)C=C1)F FCTRBCMNBYFRQU-UHFFFAOYSA-N 0.000 description 2
- UPCUUUGFMRTSCS-UHFFFAOYSA-N 4-methoxy-6-(1,3-oxazol-2-yl)-1,2-benzoxazol-3-amine Chemical compound COC1=CC(=CC2=C1C(=NO2)N)C=1OC=CN=1 UPCUUUGFMRTSCS-UHFFFAOYSA-N 0.000 description 2
- NUZVIZYRLWHCMB-UHFFFAOYSA-N 4-methoxy-6-(2,2,2-trifluoroethoxymethyl)-1,2-benzoxazol-3-amine Chemical compound COC1=CC(=CC2=C1C(=NO2)N)COCC(F)(F)F NUZVIZYRLWHCMB-UHFFFAOYSA-N 0.000 description 2
- JGULCZFECNLRJP-UHFFFAOYSA-N 4-methoxy-6-phenyl-1,2-benzoxazol-3-amine Chemical compound COC1=CC(=CC2=C1C(=NO2)N)C1=CC=CC=C1 JGULCZFECNLRJP-UHFFFAOYSA-N 0.000 description 2
- ZXVIPLDSBVGPGC-UHFFFAOYSA-N 4-methoxy-6-pyridin-2-yl-1,2-benzoxazol-3-amine Chemical compound COC1=CC(=CC2=C1C(=NO2)N)C1=NC=CC=C1 ZXVIPLDSBVGPGC-UHFFFAOYSA-N 0.000 description 2
- CWUBLUOKKQYNNK-UHFFFAOYSA-N 4-methoxy-7-(1-methylpyrazol-4-yl)-1,2-benzoxazol-3-amine Chemical compound COC1=CC=C(C2=C1C(=NO2)N)C=1C=NN(C=1)C CWUBLUOKKQYNNK-UHFFFAOYSA-N 0.000 description 2
- ZLTCXTRHEQUDGV-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)CC2 ZLTCXTRHEQUDGV-UHFFFAOYSA-N 0.000 description 2
- CKQWMCTVZYPORF-UHFFFAOYSA-N 5-(trifluoromethoxy)-1,2-benzoxazol-3-amine Chemical compound Nc1noc2ccc(OC(F)(F)F)cc12 CKQWMCTVZYPORF-UHFFFAOYSA-N 0.000 description 2
- WDCSWTWTTAMPFJ-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1-benzofuran-7-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC(Br)=CC2=C1OCC2 WDCSWTWTTAMPFJ-UHFFFAOYSA-N 0.000 description 2
- TVQGEMZMXVGMCR-UHFFFAOYSA-N 5-chloro-1,2-benzoxazol-3-amine Chemical compound C1=C(Cl)C=C2C(N)=NOC2=C1 TVQGEMZMXVGMCR-UHFFFAOYSA-N 0.000 description 2
- PWFGVISPJXAHFF-UHFFFAOYSA-N 5-ethoxy-2-fluorobenzonitrile Chemical compound CCOC1=CC=C(F)C(C#N)=C1 PWFGVISPJXAHFF-UHFFFAOYSA-N 0.000 description 2
- INMCFWIEXUDNTJ-UHFFFAOYSA-N 5-ethyl-1-methylpyridin-2-one Chemical compound CCC=1C=CC(=O)N(C)C=1 INMCFWIEXUDNTJ-UHFFFAOYSA-N 0.000 description 2
- ORMQFHJGBAPKHK-UHFFFAOYSA-N 5-ethyl-1h-pyridin-2-one Chemical compound CCC=1C=CC(=O)NC=1 ORMQFHJGBAPKHK-UHFFFAOYSA-N 0.000 description 2
- WOSJQXCRYIYFKT-UHFFFAOYSA-N 5-ethyl-2-methoxypyridine Chemical compound CCC1=CC=C(OC)N=C1 WOSJQXCRYIYFKT-UHFFFAOYSA-N 0.000 description 2
- MFOFRTNLDVCUMG-UHFFFAOYSA-N 5-ethyl-N-(7-fluoro-1,2-benzoxazol-3-yl)-2-methoxybenzenesulfonamide Chemical compound C(C)C=1C=CC(=C(C=1)S(=O)(=O)NC1=NOC2=C1C=CC=C2F)OC MFOFRTNLDVCUMG-UHFFFAOYSA-N 0.000 description 2
- IKFWQARCTWJABA-UHFFFAOYSA-N 5-methoxy-1,2-benzoxazol-3-amine Chemical compound COC1=CC=C2ON=C(N)C2=C1 IKFWQARCTWJABA-UHFFFAOYSA-N 0.000 description 2
- GNWQLQVKOQHMPF-UHFFFAOYSA-N 5-methyl-1,2-benzoxazol-3-amine Chemical compound CC1=CC=C2ON=C(N)C2=C1 GNWQLQVKOQHMPF-UHFFFAOYSA-N 0.000 description 2
- NJAHODQQWBYBCG-UHFFFAOYSA-N 5-methyl-6-(1,3-oxazol-2-yl)-1,2-benzoxazol-3-amine Chemical compound CC=1C(=CC2=C(C(=NO2)N)C=1)C=1OC=CN=1 NJAHODQQWBYBCG-UHFFFAOYSA-N 0.000 description 2
- OULFLCIKERGWAD-UHFFFAOYSA-N 5-methyl-6-pyridin-2-yl-1,2-benzoxazol-3-amine Chemical compound CC=1C(=CC2=C(C(=NO2)N)C=1)C1=NC=CC=C1 OULFLCIKERGWAD-UHFFFAOYSA-N 0.000 description 2
- CUQBXCGHRKXDPK-UHFFFAOYSA-N 6-(1,3-oxazol-2-yl)-1,2-benzoxazol-3-amine Chemical compound O1C(=NC=C1)C1=CC2=C(C(=NO2)N)C=C1 CUQBXCGHRKXDPK-UHFFFAOYSA-N 0.000 description 2
- YWAAFIRWNMIHCB-UHFFFAOYSA-N 6-(3,5-dimethylpyrazol-1-yl)-1,2-benzoxazol-3-amine Chemical compound CC1=NN(C(=C1)C)C1=CC2=C(C(=NO2)N)C=C1 YWAAFIRWNMIHCB-UHFFFAOYSA-N 0.000 description 2
- MRDNYOYHAKNUTO-UHFFFAOYSA-N 6-(cyclopropylmethoxy)-1,2-benzoxazol-3-amine Chemical compound C1=C2C(N)=NOC2=CC(OCC2CC2)=C1 MRDNYOYHAKNUTO-UHFFFAOYSA-N 0.000 description 2
- OCEATWWFTJKLAY-UHFFFAOYSA-N 6-(difluoromethoxy)-4-methoxy-1,2-benzoxazol-3-amine Chemical compound FC(OC1=CC2=C(C(=NO2)N)C(=C1)OC)F OCEATWWFTJKLAY-UHFFFAOYSA-N 0.000 description 2
- BYSQWNNLFBOKNU-UHFFFAOYSA-N 6-(ethoxymethyl)-4-methoxy-1,2-benzoxazol-3-amine Chemical compound C(C)OCC1=CC2=C(C(=NO2)N)C(=C1)OC BYSQWNNLFBOKNU-UHFFFAOYSA-N 0.000 description 2
- SPAPEMGSMUESHB-UHFFFAOYSA-N 6-(oxan-2-yloxy)-1,2-benzoxazol-3-amine Chemical compound C=1C=C2C(N)=NOC2=CC=1OC1CCCCO1 SPAPEMGSMUESHB-UHFFFAOYSA-N 0.000 description 2
- YYARAEYQQQJJTK-UHFFFAOYSA-N 6-(triazol-1-yl)-1,2-benzoxazol-3-amine Chemical compound N1(N=NC=C1)C1=CC2=C(C(=NO2)N)C=C1 YYARAEYQQQJJTK-UHFFFAOYSA-N 0.000 description 2
- HAMRSHBKPWFVJA-UHFFFAOYSA-N 6-(triazol-2-yl)-1,2-benzoxazol-3-amine Chemical compound N=1N(N=CC=1)C1=CC2=C(C(=NO2)N)C=C1 HAMRSHBKPWFVJA-UHFFFAOYSA-N 0.000 description 2
- FIQGCIKKZIDZOM-UHFFFAOYSA-N 6-bromo-4-methoxy-1,2-benzoxazol-3-amine Chemical compound O(C1=C2C(N)=NOC2=CC(Br)=C1)C FIQGCIKKZIDZOM-UHFFFAOYSA-N 0.000 description 2
- GKRXBWCIINBBSH-UHFFFAOYSA-N 6-pyrazol-1-yl-1,2-benzoxazol-3-amine Chemical compound N1(N=CC=C1)C1=CC2=C(C(=NO2)N)C=C1 GKRXBWCIINBBSH-UHFFFAOYSA-N 0.000 description 2
- POSSLUAPRUFRAG-UHFFFAOYSA-N 6-pyridin-2-yl-1,2-benzoxazol-3-amine Chemical compound N1=C(C=CC=C1)C1=CC2=C(C(=NO2)N)C=C1 POSSLUAPRUFRAG-UHFFFAOYSA-N 0.000 description 2
- IDWDUTBBEXGLGQ-UHFFFAOYSA-N 6-pyrimidin-2-yl-1,2-benzoxazol-3-amine Chemical compound N1=C(N=CC=C1)C1=CC2=C(C(=NO2)N)C=C1 IDWDUTBBEXGLGQ-UHFFFAOYSA-N 0.000 description 2
- FXRZDMIQAFXNEB-UHFFFAOYSA-N 7-(cyclopropylmethoxy)-1,2-benzoxazol-3-amine Chemical compound C1(CC1)COC1=CC=CC=2C(=NOC=21)N FXRZDMIQAFXNEB-UHFFFAOYSA-N 0.000 description 2
- UVIIPEZSYZNVET-UHFFFAOYSA-N 7-bromo-1,2-benzoxazol-3-amine Chemical compound C1=CC=C2C(N)=NOC2=C1Br UVIIPEZSYZNVET-UHFFFAOYSA-N 0.000 description 2
- AKARZTWPNMKZKC-UHFFFAOYSA-N 7-fluoro-1,2-benzoxazol-3-amine Chemical compound C1=CC=C2C(N)=NOC2=C1F AKARZTWPNMKZKC-UHFFFAOYSA-N 0.000 description 2
- BOYGXUWPYKJSSH-UHFFFAOYSA-N 7-methoxyquinoline-8-sulfonyl chloride Chemical compound COc1ccc2cccnc2c1S(Cl)(=O)=O BOYGXUWPYKJSSH-UHFFFAOYSA-N 0.000 description 2
- XEXJMLWFKAOYSZ-UHFFFAOYSA-N 7-pyrimidin-2-yl-1,2-benzoxazol-3-amine Chemical compound N1=C(N=CC=C1)C1=CC=CC=2C(=NOC=21)N XEXJMLWFKAOYSZ-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- AIRHNAJRBZQUEV-UHFFFAOYSA-N BrC1=CC(=CC=2C(=NOC=21)N)C Chemical compound BrC1=CC(=CC=2C(=NOC=21)N)C AIRHNAJRBZQUEV-UHFFFAOYSA-N 0.000 description 2
- KPGJEXZQSFSJNZ-UHFFFAOYSA-N BrC=1C(=C(C#N)C=C(C=1)C)F Chemical compound BrC=1C(=C(C#N)C=C(C=1)C)F KPGJEXZQSFSJNZ-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 2
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 2
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 2
- 102100029896 Bromodomain-containing protein 8 Human genes 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- WSPHYTHNDCJJIG-UHFFFAOYSA-N COCc1ccc(C#N)c(F)c1 Chemical compound COCc1ccc(C#N)c(F)c1 WSPHYTHNDCJJIG-UHFFFAOYSA-N 0.000 description 2
- 108010040163 CREB-Binding Protein Proteins 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282575 Gorilla Species 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 2
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 2
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 2
- 101000794020 Homo sapiens Bromodomain-containing protein 8 Proteins 0.000 description 2
- 241000282620 Hylobates sp. Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 108700041619 Myeloid Ecotropic Viral Integration Site 1 Proteins 0.000 description 2
- 102000047831 Myeloid Ecotropic Viral Integration Site 1 Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- NHKNZRKGWHRXCC-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)benzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=CC=C1 NHKNZRKGWHRXCC-UHFFFAOYSA-N 0.000 description 2
- DMKLPMOILMNFMR-UHFFFAOYSA-N N-(4-chloro-5-methyl-1,2-benzoxazol-3-yl)-5-ethyl-2-methoxybenzenesulfonamide Chemical compound ClC1=C(C=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC(=C1)CC)OC)C DMKLPMOILMNFMR-UHFFFAOYSA-N 0.000 description 2
- IEFPCZMYDJXWIW-UHFFFAOYSA-N N-(5-chloro-1,2-benzoxazol-3-yl)-5-ethyl-2-methoxybenzenesulfonamide Chemical compound ClC=1C=CC2=C(C(=NO2)NS(=O)(=O)C2=C(C=CC(=C2)CC)OC)C=1 IEFPCZMYDJXWIW-UHFFFAOYSA-N 0.000 description 2
- NOMCGTDESFDZFJ-UHFFFAOYSA-N N-(benzenesulfonyl)-N-(4-chloro-1,2-benzoxazol-3-yl)benzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)N(S(=O)(=O)C1=CC=CC=C1)S(=O)(=O)C1=CC=CC=C1 NOMCGTDESFDZFJ-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000397 acetylating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 150000001639 boron compounds Chemical class 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229960002412 cediranib Drugs 0.000 description 2
- 229910052801 chlorine Chemical group 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 125000002587 enol group Chemical group 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- YEAFFGRKKDDFCH-UHFFFAOYSA-N methyl 4-cyano-3-fluoro-5-methoxybenzoate Chemical compound COC(=O)c1cc(F)c(C#N)c(OC)c1 YEAFFGRKKDDFCH-UHFFFAOYSA-N 0.000 description 2
- TZRYTXCWHNTTOG-UHFFFAOYSA-N methyl 4-cyano-5-fluoro-2-methylbenzoate Chemical compound C(#N)C1=CC(=C(C(=O)OC)C=C1F)C TZRYTXCWHNTTOG-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002891 organic anions Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- ZTYZEUXZHGOXRT-UHFFFAOYSA-N quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)N)=CC=CC2=C1 ZTYZEUXZHGOXRT-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- YOWGRWHKDCHINP-UHFFFAOYSA-N tributyl(1,3-oxazol-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CO1 YOWGRWHKDCHINP-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229950000578 vatalanib Drugs 0.000 description 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- JRHPOFJADXHYBR-YUMQZZPRSA-N (1s,2s)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@H]1CCCC[C@@H]1NC JRHPOFJADXHYBR-YUMQZZPRSA-N 0.000 description 1
- SQTUYFKNCCBFRR-UHFFFAOYSA-N (2,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(OC)=C1 SQTUYFKNCCBFRR-UHFFFAOYSA-N 0.000 description 1
- MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
- WFWQWTPAPNEOFE-UHFFFAOYSA-N (3-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(O)=C1 WFWQWTPAPNEOFE-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- RHFWLPWDOYJEAL-UHFFFAOYSA-N 1,2-oxazol-3-amine Chemical compound NC=1C=CON=1 RHFWLPWDOYJEAL-UHFFFAOYSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- QRADKVYIJIAENZ-UHFFFAOYSA-N 1-[[bromo(difluoro)methyl]-ethoxyphosphoryl]oxyethane Chemical compound CCOP(=O)(C(F)(F)Br)OCC QRADKVYIJIAENZ-UHFFFAOYSA-N 0.000 description 1
- KRWRFIMBWRVMKE-UHFFFAOYSA-N 1-bromo-3,5-dimethoxybenzene Chemical compound COC1=CC(Br)=CC(OC)=C1 KRWRFIMBWRVMKE-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- KGYXKRGMSUHYCY-UHFFFAOYSA-N 1-bromo-4-fluoro-2-methoxybenzene Chemical compound COC1=CC(F)=CC=C1Br KGYXKRGMSUHYCY-UHFFFAOYSA-N 0.000 description 1
- ZRJGNCLNUWKEFU-UHFFFAOYSA-N 1-methoxy-4-phenoxybenzene Chemical compound C1=CC(OC)=CC=C1OC1=CC=CC=C1 ZRJGNCLNUWKEFU-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- IEMAOEFPZAIMCN-UHFFFAOYSA-N 1H-pyrazole Chemical compound C=1C=NNC=1.C=1C=NNC=1 IEMAOEFPZAIMCN-UHFFFAOYSA-N 0.000 description 1
- MREIFUWKYMNYTK-UHFFFAOYSA-N 1H-pyrrole Chemical compound C=1C=CNC=1.C=1C=CNC=1 MREIFUWKYMNYTK-UHFFFAOYSA-N 0.000 description 1
- HUEXNHSMABCRTH-UHFFFAOYSA-N 1h-imidazole Chemical compound C1=CNC=N1.C1=CNC=N1 HUEXNHSMABCRTH-UHFFFAOYSA-N 0.000 description 1
- WULMXCYJXGAWHW-UHFFFAOYSA-N 1h-indene-5-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C2CC=CC2=C1 WULMXCYJXGAWHW-UHFFFAOYSA-N 0.000 description 1
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- GKPHNZYMLJPYJJ-UHFFFAOYSA-N 2,3-difluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1F GKPHNZYMLJPYJJ-UHFFFAOYSA-N 0.000 description 1
- DFPWTOVZVNDCSL-UHFFFAOYSA-N 2,4,6-trimethoxy-N-(4-methoxy-1,2-benzoxazol-3-yl)benzenesulfonamide Chemical compound COC1=C(C(=CC(=C1)OC)OC)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)OC DFPWTOVZVNDCSL-UHFFFAOYSA-N 0.000 description 1
- AAGNQZFPUZSYHX-UHFFFAOYSA-N 2,4-dimethoxy-N-(4-methoxy-1,2-benzoxazol-3-yl)benzenesulfonamide Chemical compound COC1=C(C=CC(=C1)OC)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)OC AAGNQZFPUZSYHX-UHFFFAOYSA-N 0.000 description 1
- AYGZKRRIULCJKC-UHFFFAOYSA-N 2,4-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C(OC)=C1 AYGZKRRIULCJKC-UHFFFAOYSA-N 0.000 description 1
- KEIYYIGMDPTAPL-UHFFFAOYSA-N 2,6-difluoro-4-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(C#N)C(F)=C1 KEIYYIGMDPTAPL-UHFFFAOYSA-N 0.000 description 1
- QQGWTWHZSMHQDW-UHFFFAOYSA-N 2,6-dimethoxy-N-(4-methoxy-1,2-benzoxazol-3-yl)benzenesulfonamide Chemical compound COC1=C(C(=CC=C1)OC)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)OC QQGWTWHZSMHQDW-UHFFFAOYSA-N 0.000 description 1
- QLRKALMVPCQTMU-UHFFFAOYSA-N 2-bromo-1-fluoro-4-methylbenzene Chemical compound CC1=CC=C(F)C(Br)=C1 QLRKALMVPCQTMU-UHFFFAOYSA-N 0.000 description 1
- IELGUZKHALDFOO-UHFFFAOYSA-N 2-bromo-6-fluorobenzonitrile Chemical compound FC1=CC=CC(Br)=C1C#N IELGUZKHALDFOO-UHFFFAOYSA-N 0.000 description 1
- UHLLSLUQSGFENQ-UHFFFAOYSA-N 2-chloro-6-fluoro-3-methylbenzonitrile Chemical compound CC1=CC=C(F)C(C#N)=C1Cl UHLLSLUQSGFENQ-UHFFFAOYSA-N 0.000 description 1
- XPTAYRHLHAFUOS-UHFFFAOYSA-N 2-chloro-6-fluorobenzonitrile Chemical compound FC1=CC=CC(Cl)=C1C#N XPTAYRHLHAFUOS-UHFFFAOYSA-N 0.000 description 1
- WQWQHJNUHQEGTN-UHFFFAOYSA-N 2-chloro-6-methylbenzonitrile Chemical compound CC1=CC=CC(Cl)=C1C#N WQWQHJNUHQEGTN-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- FIAJEHSGNSSUOQ-UHFFFAOYSA-N 2-fluoro-4-(5-trimethylsilyltriazol-1-yl)benzonitrile Chemical compound FC1=C(C#N)C=CC(=C1)N1N=NC=C1[Si](C)(C)C FIAJEHSGNSSUOQ-UHFFFAOYSA-N 0.000 description 1
- WLQHJQUGYACADR-UHFFFAOYSA-N 2-fluoro-4-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=C(C#N)C(F)=C1 WLQHJQUGYACADR-UHFFFAOYSA-N 0.000 description 1
- REIVHYDACHXPNH-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzonitrile Chemical compound OC1=CC=C(C#N)C(F)=C1 REIVHYDACHXPNH-UHFFFAOYSA-N 0.000 description 1
- MFLGNKVMGUFLOV-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethoxy)benzonitrile Chemical compound FC1=CC=C(OC(F)(F)F)C=C1C#N MFLGNKVMGUFLOV-UHFFFAOYSA-N 0.000 description 1
- CMAOLVNGLTWICC-UHFFFAOYSA-N 2-fluoro-5-methylbenzonitrile Chemical compound CC1=CC=C(F)C(C#N)=C1 CMAOLVNGLTWICC-UHFFFAOYSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- YEBHNFDMNFHZFF-UHFFFAOYSA-N 2-fluoro-6-hydroxybenzonitrile Chemical compound OC1=CC=CC(F)=C1C#N YEBHNFDMNFHZFF-UHFFFAOYSA-N 0.000 description 1
- YPMSIWYNTPSPMV-UHFFFAOYSA-N 2-fluoro-6-methoxybenzonitrile Chemical compound COC1=CC=CC(F)=C1C#N YPMSIWYNTPSPMV-UHFFFAOYSA-N 0.000 description 1
- DOHMTOMVCPKOEE-UHFFFAOYSA-N 2-fluoro-6-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1C#N DOHMTOMVCPKOEE-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- RMNWBJSMQFRHKQ-UHFFFAOYSA-N 2-methoxy-N-(4-methoxy-1,2-benzoxazol-3-yl)-4,6-dimethylbenzenesulfonamide Chemical compound COC1=C(C(=CC(=C1)C)C)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)OC RMNWBJSMQFRHKQ-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- LMBOJOXVLORKSQ-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC(CCC(O)=O)=CC(OC)=C1 LMBOJOXVLORKSQ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- HETQAZPBCKXNEF-UHFFFAOYSA-N 3-chloro-N-(4-chloro-1,2-benzoxazol-3-yl)-4-methylbenzenesulfonamide Chemical compound ClC=1C=C(C=CC=1C)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)Cl HETQAZPBCKXNEF-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- AHKFYDCXTDAIDP-UHFFFAOYSA-N 4-(difluoromethoxy)-2-fluoro-6-methoxybenzonitrile Chemical compound FC(OC1=CC(=C(C#N)C(=C1)OC)F)F AHKFYDCXTDAIDP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
- FDUGOYTWYJZNNP-UHFFFAOYSA-N 4-amino-2-fluorobenzonitrile Chemical compound NC1=CC=C(C#N)C(F)=C1 FDUGOYTWYJZNNP-UHFFFAOYSA-N 0.000 description 1
- TZHQWUAOIWRFSW-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzonitrile Chemical compound FC1=CC(Br)=CC(F)=C1C#N TZHQWUAOIWRFSW-UHFFFAOYSA-N 0.000 description 1
- ITLUZVHBLWMNIG-UHFFFAOYSA-N 4-chloro-N-(4-chloro-1,2-benzoxazol-3-yl)benzenesulfonamide Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)Cl ITLUZVHBLWMNIG-UHFFFAOYSA-N 0.000 description 1
- ZWKNDLMYSLLMRF-UHFFFAOYSA-N 4-cyano-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C(F)=C1 ZWKNDLMYSLLMRF-UHFFFAOYSA-N 0.000 description 1
- YYCPEUWXNKDHQE-UHFFFAOYSA-N 4-fluoro-1,2-benzoxazol-3-amine Chemical compound C1=CC(F)=C2C(N)=NOC2=C1 YYCPEUWXNKDHQE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- DBCGKTPWOKOECY-UHFFFAOYSA-N 4-methoxy-N-(4-methoxy-1,2-benzoxazol-3-yl)quinoline-8-sulfonamide Chemical compound COC1=CC=NC2=C(C=CC=C12)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)OC DBCGKTPWOKOECY-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- JSNDPQMTXGDMIM-UHFFFAOYSA-N 4-nitro-1,2-benzoxazol-3-amine Chemical compound C1=CC([N+]([O-])=O)=C2C(N)=NOC2=C1 JSNDPQMTXGDMIM-UHFFFAOYSA-N 0.000 description 1
- OWDWFHKROAVOKX-UHFFFAOYSA-N 4-tert-butyl-N-(4-chloro-1,2-benzoxazol-3-yl)benzenesulfonamide Chemical compound C(C)(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)Cl OWDWFHKROAVOKX-UHFFFAOYSA-N 0.000 description 1
- GNHHFRQMAKLFRU-UHFFFAOYSA-N 5-(difluoromethoxy)-1-fluoro-2-isocyano-3-methoxybenzene Chemical compound FC(OC=1C=C(C(=C(C=1)F)[N+]#[C-])OC)F GNHHFRQMAKLFRU-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- UDWFSJAYXTXMLM-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1-benzofuran Chemical compound BrC1=CC=C2OCCC2=C1 UDWFSJAYXTXMLM-UHFFFAOYSA-N 0.000 description 1
- GYCNHFWRPJXTSB-UHFFFAOYSA-N 5-bromo-2-fluorobenzonitrile Chemical compound FC1=CC=C(Br)C=C1C#N GYCNHFWRPJXTSB-UHFFFAOYSA-N 0.000 description 1
- XADICJHFELMBGX-UHFFFAOYSA-N 5-bromo-2-methoxypyridine Chemical compound COC1=CC=C(Br)C=N1 XADICJHFELMBGX-UHFFFAOYSA-N 0.000 description 1
- VUGRLJJCZUTHRT-UHFFFAOYSA-N 5-bromo-N-(4-chloro-1,2-benzoxazol-3-yl)-2-methoxybenzenesulfonamide Chemical compound BrC=1C=CC(=C(C=1)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)Cl)OC VUGRLJJCZUTHRT-UHFFFAOYSA-N 0.000 description 1
- GJNJDELEHIGPKJ-UHFFFAOYSA-N 5-chloro-2-fluorobenzonitrile Chemical compound FC1=CC=C(Cl)C=C1C#N GJNJDELEHIGPKJ-UHFFFAOYSA-N 0.000 description 1
- OHNBMAWXJGFGRZ-UHFFFAOYSA-N 5-chloro-4-methoxy-6-(methoxymethyl)-1,2-benzoxazol-3-amine Chemical compound O(C)C1=C(C(COC)=CC2=C1C(N)=NO2)Cl OHNBMAWXJGFGRZ-UHFFFAOYSA-N 0.000 description 1
- WPPWEFVZGFJESZ-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-indene Chemical compound COC1=CC=C2CCCC2=C1 WPPWEFVZGFJESZ-UHFFFAOYSA-N 0.000 description 1
- JAEZJGZLSDFRBD-UHFFFAOYSA-N 5-tert-butyl-N-(4-chloro-1,2-benzoxazol-3-yl)-2-methoxybenzenesulfonamide Chemical compound C(C)(C)(C)C=1C=CC(=C(C=1)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)Cl)OC JAEZJGZLSDFRBD-UHFFFAOYSA-N 0.000 description 1
- VUMFEESWELAKKV-UHFFFAOYSA-N 6-chloro-1,2-benzoxazol-3-amine Chemical compound ClC1=CC=C2C(N)=NOC2=C1 VUMFEESWELAKKV-UHFFFAOYSA-N 0.000 description 1
- SUFDFKRJYKNTFH-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydronaphthalene Chemical compound C1CCCC2=CC(OC)=CC=C21 SUFDFKRJYKNTFH-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- DLZFYFNXRCXTPK-UHFFFAOYSA-N 7-iodo-4-methoxy-6-(methoxymethyl)-1,2-benzoxazol-3-amine Chemical compound IC1=C(C=C(C=2C(=NOC=21)N)OC)COC DLZFYFNXRCXTPK-UHFFFAOYSA-N 0.000 description 1
- IVHJSNNMKJWPFW-UHFFFAOYSA-N 7-methoxyquinoline Chemical compound C1=CC=NC2=CC(OC)=CC=C21 IVHJSNNMKJWPFW-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108091052242 Bromo- and Extra-Terminal domain (BET) family Proteins 0.000 description 1
- 102100029897 Bromodomain-containing protein 7 Human genes 0.000 description 1
- 102100029893 Bromodomain-containing protein 9 Human genes 0.000 description 1
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- YUKYVUHULHUJSC-CNLJRFSTSA-N C(C)O.C(O[2H])([2H])([2H])[2H].CO Chemical class C(C)O.C(O[2H])([2H])([2H])[2H].CO YUKYVUHULHUJSC-CNLJRFSTSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000006964 Chan-Lam coupling reaction Methods 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000017589 Chromo domains Human genes 0.000 description 1
- 108050005811 Chromo domains Proteins 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108700000281 Drosophila mof Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010057649 Endometrial sarcoma Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000794019 Homo sapiens Bromodomain-containing protein 7 Proteins 0.000 description 1
- 101000794032 Homo sapiens Bromodomain-containing protein 9 Proteins 0.000 description 1
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 101000596093 Homo sapiens Transcription initiation factor TFIID subunit 1 Proteins 0.000 description 1
- 101000596092 Homo sapiens Transcription initiation factor TFIID subunit 1-like Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 108010075710 Lysine Acetyltransferase 5 Proteins 0.000 description 1
- 108010033293 Lysine Acetyltransferases Proteins 0.000 description 1
- 102000007077 Lysine Acetyltransferases Human genes 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 101150029107 MEIS1 gene Proteins 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000289390 Monotremata Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101100178928 Mus musculus Hoxa9 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- RZYMEWWCVDKCLY-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2,3-dichlorobenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C(=CC=C1)Cl)Cl RZYMEWWCVDKCLY-UHFFFAOYSA-N 0.000 description 1
- UJEATBSVAGQWFT-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2,3-dihydro-1H-indene-5-sulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C=1C=C2CCCC2=CC=1 UJEATBSVAGQWFT-UHFFFAOYSA-N 0.000 description 1
- KRQYDADGSJMLJO-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2,4-dichlorobenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=C(C=C1)Cl)Cl KRQYDADGSJMLJO-UHFFFAOYSA-N 0.000 description 1
- PGCQFBTXLYIKHO-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2,4-dimethoxybenzenesulfonamide Chemical compound O(C1=CC=C(S(=O)(=O)NC=2C3=CC=CC=C3ON=2)C(OC)=C1)C PGCQFBTXLYIKHO-UHFFFAOYSA-N 0.000 description 1
- MOHITILXFBRMKR-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2,5-diethylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=CC(=C1)CC)CC MOHITILXFBRMKR-UHFFFAOYSA-N 0.000 description 1
- BJTYYEYAGADDDC-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2,5-dimethoxybenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=CC(=C1)OC)OC BJTYYEYAGADDDC-UHFFFAOYSA-N 0.000 description 1
- CKARKBUIIMYJNW-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2,6-dimethoxybenzenesulfonamide Chemical compound C1=CC=C(C(=C1OC)S(=O)(=O)NC=1C2=C(ON=1)C=CC=C2)OC CKARKBUIIMYJNW-UHFFFAOYSA-N 0.000 description 1
- AZXPTJPTIMFDBG-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2-ethoxy-5-ethylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=CC(=C1)CC)OCC AZXPTJPTIMFDBG-UHFFFAOYSA-N 0.000 description 1
- BABOHBCIKVNWGZ-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2-methoxy-5-(1,2-oxazol-5-yl)benzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=CC(=C1)C1=CC=NO1)OC BABOHBCIKVNWGZ-UHFFFAOYSA-N 0.000 description 1
- ZCGQQHYRLSQIGN-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2-methoxy-5-propan-2-ylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=CC(=C1)C(C)C)OC ZCGQQHYRLSQIGN-UHFFFAOYSA-N 0.000 description 1
- SYCKCXUOLUNGHD-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2-methoxy-5-pyrazol-1-ylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=CC(=C1)N1N=CC=C1)OC SYCKCXUOLUNGHD-UHFFFAOYSA-N 0.000 description 1
- RDASFZGNUGZEAY-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-2-methoxybenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=CC=C1)OC RDASFZGNUGZEAY-UHFFFAOYSA-N 0.000 description 1
- QBGJCPNWLAWTIA-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-3,4-dichlorobenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=CC(=C(C=C1)Cl)Cl QBGJCPNWLAWTIA-UHFFFAOYSA-N 0.000 description 1
- WPSVOWUDLTZTOV-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-3-(5-methyl-1,3,4-oxadiazol-2-yl)benzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=CC(=CC=C1)C=1OC(=NN=1)C WPSVOWUDLTZTOV-UHFFFAOYSA-N 0.000 description 1
- NWBFLRSNUISOBM-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-3-chloro-2-methylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C(=CC=C1)Cl)C NWBFLRSNUISOBM-UHFFFAOYSA-N 0.000 description 1
- OKXAXMBYWXUSCW-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-3-ethylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=CC(=CC=C1)CC OKXAXMBYWXUSCW-UHFFFAOYSA-N 0.000 description 1
- HKTKINKCRFKJPV-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-3-phenylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C=1C=C(C=CC=1)C1=CC=CC=C1 HKTKINKCRFKJPV-UHFFFAOYSA-N 0.000 description 1
- WVXBFEXWCADXNY-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-4-cyclohexylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=CC=C(C=C1)C1CCCCC1 WVXBFEXWCADXNY-UHFFFAOYSA-N 0.000 description 1
- SJCOKWVHGFSRAB-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-4-ethylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=CC=C(C=C1)CC SJCOKWVHGFSRAB-UHFFFAOYSA-N 0.000 description 1
- JMQTVVBOGQGTCS-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-4-phenylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1 JMQTVVBOGQGTCS-UHFFFAOYSA-N 0.000 description 1
- HGMLMAJPYNDNEU-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=CC=2CCCCC=2C=C1 HGMLMAJPYNDNEU-UHFFFAOYSA-N 0.000 description 1
- JHENHJCXPUHIQZ-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-5-bromopyridine-2-sulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=NC=C(C=C1)Br JHENHJCXPUHIQZ-UHFFFAOYSA-N 0.000 description 1
- JKIHEFGSLWGYAX-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-5-chloro-2-methoxy-4-methylbenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=C(C(=C1)Cl)C)OC JKIHEFGSLWGYAX-UHFFFAOYSA-N 0.000 description 1
- XZCVRCRHPFUWMX-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)-5-tert-butyl-2-methoxybenzenesulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=C(C=CC(=C1)C(C)(C)C)OC XZCVRCRHPFUWMX-UHFFFAOYSA-N 0.000 description 1
- FLMQADBABFOSDT-UHFFFAOYSA-N N-(1,2-benzoxazol-3-yl)naphthalene-2-sulfonamide Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C1=CC2=CC=CC=C2C=C1 FLMQADBABFOSDT-UHFFFAOYSA-N 0.000 description 1
- CFMMGHKHVDYIMH-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-1,3-benzothiazole-4-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=CC=C2C=1N=CS2 CFMMGHKHVDYIMH-UHFFFAOYSA-N 0.000 description 1
- CKSBFYQZZBEDPF-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2,1,3-benzoxadiazole-4-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=CC2=NON=C21 CKSBFYQZZBEDPF-UHFFFAOYSA-N 0.000 description 1
- HIECFIBAPSCCAA-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2,3-dihydro-1,4-benzodioxine-5-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=CC=2OCCOC=21 HIECFIBAPSCCAA-UHFFFAOYSA-N 0.000 description 1
- JEBPNLCXLBJSFH-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2,3-dihydro-1H-indene-5-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=C2CCCC2=CC=1 JEBPNLCXLBJSFH-UHFFFAOYSA-N 0.000 description 1
- XYCWJWVHSDPVTB-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2,6-difluorobenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC=C1F)F XYCWJWVHSDPVTB-UHFFFAOYSA-N 0.000 description 1
- RVFBUOJPZVTCQJ-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-(1,3-oxazol-5-yl)benzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC=C1)C1=CN=CO1 RVFBUOJPZVTCQJ-UHFFFAOYSA-N 0.000 description 1
- XJLSMFQNHFUJTQ-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-fluorobenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC=C1)F XJLSMFQNHFUJTQ-UHFFFAOYSA-N 0.000 description 1
- FEGMHYSOEREEER-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-methoxy-4,5-dimethylbenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=C(C(=C1)C)C)OC FEGMHYSOEREEER-UHFFFAOYSA-N 0.000 description 1
- HQOXFILPTJOIRR-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-methoxy-4-methyl-5-propan-2-ylbenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=C(C(=C1)C(C)C)C)OC HQOXFILPTJOIRR-UHFFFAOYSA-N 0.000 description 1
- HFMWUTPUTPEFBS-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-methoxy-5-propan-2-ylbenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC(=C1)C(C)C)OC HFMWUTPUTPEFBS-UHFFFAOYSA-N 0.000 description 1
- FARHBFJWMVSOEW-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-methoxybenzenesulfonamide Chemical compound O(C)C1=C(C=CC=C1)S(=O)(=O)NC=1C2=C(ON=1)C=CC=C2Cl FARHBFJWMVSOEW-UHFFFAOYSA-N 0.000 description 1
- AZEYCNSPPPWWMG-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-methyl-5-(1,2-oxazol-5-yl)benzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC(=C1)C1=CC=NO1)C AZEYCNSPPPWWMG-UHFFFAOYSA-N 0.000 description 1
- VMPLTVXVUDAVNM-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-methyl-5-(2-methyl-1,3-oxazol-5-yl)benzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC(=C1)C1=CN=C(O1)C)C VMPLTVXVUDAVNM-UHFFFAOYSA-N 0.000 description 1
- NJRWUUHMZCGAIR-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-methyl-5-pyrazol-1-ylbenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC(=C1)N1N=CC=C1)C NJRWUUHMZCGAIR-UHFFFAOYSA-N 0.000 description 1
- GNYBXFWOHIMECB-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-methylbenzotriazole-4-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=CC2=NN(N=C21)C GNYBXFWOHIMECB-UHFFFAOYSA-N 0.000 description 1
- OSRZEJOUAQKYDV-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-oxo-3H-1,3-benzoxazole-6-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC2=C(N=C(O2)O)C=C1 OSRZEJOUAQKYDV-UHFFFAOYSA-N 0.000 description 1
- ITSFRPCXCAMTNJ-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-2-phenoxybenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC=C1)OC1=CC=CC=C1 ITSFRPCXCAMTNJ-UHFFFAOYSA-N 0.000 description 1
- KLDVSVFRZQWEND-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC2=C(OCCCO2)C=C1 KLDVSVFRZQWEND-UHFFFAOYSA-N 0.000 description 1
- QRJHXEUPBYCKQK-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-3-methyl-2-oxo-1,3-benzoxazole-6-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC2=C(N(C(O2)=O)C)C=C1 QRJHXEUPBYCKQK-UHFFFAOYSA-N 0.000 description 1
- QLYLVLOVYKXLAQ-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-3-phenylbenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=C(C=CC=1)C1=CC=CC=C1 QLYLVLOVYKXLAQ-UHFFFAOYSA-N 0.000 description 1
- KXGAOMJTFYSHKZ-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-4-methylbenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=C(C=C1)C KXGAOMJTFYSHKZ-UHFFFAOYSA-N 0.000 description 1
- PTLSITKDNHKTHH-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-4-phenylmethoxybenzenesulfonamide Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)S(=O)(=O)NC1=NOC2=C1C(=CC=C2)Cl PTLSITKDNHKTHH-UHFFFAOYSA-N 0.000 description 1
- KDCPUXXXQOBZHO-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-4-propan-2-ylbenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=C(C=C1)C(C)C KDCPUXXXQOBZHO-UHFFFAOYSA-N 0.000 description 1
- RPGPTESLJRDELD-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-4-propan-2-yloxybenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=C(C=C1)OC(C)C RPGPTESLJRDELD-UHFFFAOYSA-N 0.000 description 1
- ACFMOLMYXHLDRT-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-4-pyrazol-1-ylbenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=C(C=C1)N1N=CC=C1 ACFMOLMYXHLDRT-UHFFFAOYSA-N 0.000 description 1
- ZHKKJHZDNWYDAS-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=2CCCCC=2C=C1 ZHKKJHZDNWYDAS-UHFFFAOYSA-N 0.000 description 1
- VJJUFFJKQTXYPW-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-5-ethyl-2-methoxybenzenesulfonamide Chemical compound O(C)C1=C(C=C(C=C1)CC)S(=O)(=O)NC=1C2=C(Cl)C=CC=C2ON=1 VJJUFFJKQTXYPW-UHFFFAOYSA-N 0.000 description 1
- YVEYTIIOVMSVNW-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)-5-fluoro-2-methoxybenzenesulfonamide Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC(=C1)F)OC YVEYTIIOVMSVNW-UHFFFAOYSA-N 0.000 description 1
- CMOQCNKHCJYTBU-UHFFFAOYSA-N N-(4-chloro-1,2-benzoxazol-3-yl)isoquinoline-8-sulfonamide Chemical compound C1=NC=C2C(=C1)C=CC=C2S(=O)(=O)NC=1C2=C(ON=1)C=CC=C2Cl CMOQCNKHCJYTBU-UHFFFAOYSA-N 0.000 description 1
- ANDCJAFOIABYNH-UHFFFAOYSA-N N-(4-fluoro-1,2-benzoxazol-3-yl)-2-methoxybenzenesulfonamide Chemical compound O(C)C1=C(C=CC=C1)S(=O)(=O)NC=1C2=C(ON=1)C=CC=C2F ANDCJAFOIABYNH-UHFFFAOYSA-N 0.000 description 1
- DLWABYCNFFRSNA-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)-1-benzofuran-7-sulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=CC=CC=2C=COC=21 DLWABYCNFFRSNA-UHFFFAOYSA-N 0.000 description 1
- AVGBXXTURSDGSM-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)-2-(methoxymethyl)benzenesulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C=CC=C1)COC AVGBXXTURSDGSM-UHFFFAOYSA-N 0.000 description 1
- PIHZQVQPZHEAQJ-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)-2-methylquinoline-8-sulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=CC=C2C=CC(=NC=12)C PIHZQVQPZHEAQJ-UHFFFAOYSA-N 0.000 description 1
- YSAMFGREBKJZPE-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)-3,4-dihydro-2H-chromene-8-sulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=CC=C2CCCOC=12 YSAMFGREBKJZPE-UHFFFAOYSA-N 0.000 description 1
- GSNNILCEAJCQLB-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)-3-methylquinoline-8-sulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=CC=C2C=C(C=NC=12)C GSNNILCEAJCQLB-UHFFFAOYSA-N 0.000 description 1
- LLCCDGGGHXRUAD-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)-4-methylquinoline-8-sulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=CC=C2C(=CC=NC=12)C LLCCDGGGHXRUAD-UHFFFAOYSA-N 0.000 description 1
- YLECYXKLQLEVEA-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)-6-methylquinoline-8-sulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=C(C=C2C=CC=NC=12)C YLECYXKLQLEVEA-UHFFFAOYSA-N 0.000 description 1
- REQMLDJYMBKWPU-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)-7-methylquinoline-8-sulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C(=CC=C2C=CC=NC=12)C REQMLDJYMBKWPU-UHFFFAOYSA-N 0.000 description 1
- QEKMISPHJZRILD-UHFFFAOYSA-N N-(4-methoxy-1,2-benzoxazol-3-yl)quinoline-8-sulfonamide Chemical compound COC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C=1C=CC=C2C=CC=NC=12 QEKMISPHJZRILD-UHFFFAOYSA-N 0.000 description 1
- HZAWJGDDWDOCDR-UHFFFAOYSA-N N-(6-bromo-1,2-benzoxazol-3-yl)-2-methoxybenzenesulfonamide Chemical compound O(C)C1=C(C=CC=C1)S(=O)(=O)NC=1C2=C(ON=1)C=C(Br)C=C2 HZAWJGDDWDOCDR-UHFFFAOYSA-N 0.000 description 1
- HQBJNWXQXIZRKC-UHFFFAOYSA-N N-(6-chloro-1,2-benzoxazol-3-yl)-2-methoxybenzenesulfonamide Chemical compound O(C)C1=C(C=CC=C1)S(=O)(=O)NC=1C2=CC=C(C=C2ON=1)Cl HQBJNWXQXIZRKC-UHFFFAOYSA-N 0.000 description 1
- CNHMROMLYNGIDX-UHFFFAOYSA-N N-[7-iodo-4-methoxy-6-(methoxymethyl)-1,2-benzoxazol-3-yl]-2,6-dimethoxybenzenesulfonamide Chemical compound IC1=C(C=C(C=2C(=NOC=21)NS(=O)(=O)C1=C(C=CC=C1OC)OC)OC)COC CNHMROMLYNGIDX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000289371 Ornithorhynchus anatinus Species 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108030005449 Polo kinases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100021688 Rho guanine nucleotide exchange factor 5 Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 102000006290 Transcription Factor TFIID Human genes 0.000 description 1
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 1
- 102100035222 Transcription initiation factor TFIID subunit 1 Human genes 0.000 description 1
- 102100035238 Transcription initiation factor TFIID subunit 1-like Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000289674 Vombatidae Species 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- YGSFNCRAZOCNDJ-TXHXQZCNSA-N [2H]C(C(=O)C([2H])([2H])[2H])([2H])[2H].CC(=O)C Chemical class [2H]C(C(=O)C([2H])([2H])[2H])([2H])[2H].CC(=O)C YGSFNCRAZOCNDJ-TXHXQZCNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- PXAJQJMDEXJWFB-UHFFFAOYSA-N acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- KAOMOVYHGLSFHQ-UTOQUPLUSA-N anacardic acid Chemical class CCC\C=C/C\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O KAOMOVYHGLSFHQ-UTOQUPLUSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000003719 aurora kinase inhibitor Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- BHKICZDKIIDMNR-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound N.N.[Pt+4].[O-]C(=O)C1(C([O-])=O)CCC1 BHKICZDKIIDMNR-UHFFFAOYSA-L 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical compound [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229950002826 canertinib Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000006239 cerebral cortex development Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000000493 colon squamous cell carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000032671 dosage compensation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000002172 effect on chromatin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- WCVXAYSKMJJPLO-UHFFFAOYSA-N furan Chemical compound C=1C=COC=1.C=1C=COC=1 WCVXAYSKMJJPLO-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- UYZLXCOQEDYFRO-UHFFFAOYSA-N isoquinoline-8-sulfonyl chloride Chemical compound C1=NC=C2C(S(=O)(=O)Cl)=CC=CC2=C1 UYZLXCOQEDYFRO-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000002624 low-dose chemotherapy Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- FHSADXJTYWMSQK-UHFFFAOYSA-N methyl 2-[(4-chloro-1,2-benzoxazol-3-yl)sulfamoyl]benzoate Chemical compound ClC1=CC=CC2=C1C(=NO2)NS(=O)(=O)C1=C(C(=O)OC)C=CC=C1 FHSADXJTYWMSQK-UHFFFAOYSA-N 0.000 description 1
- ZGGOOFRENIFQOD-UHFFFAOYSA-N methyl 3-(1,2-benzoxazol-3-ylsulfamoyl)-4-methoxybenzoate Chemical compound O1N=C(C2=C1C=CC=C2)NS(=O)(=O)C=1C=C(C(=O)OC)C=CC=1OC ZGGOOFRENIFQOD-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- MSPCOXFYKUKYLB-UHFFFAOYSA-N naphthalene-1-sulfonamide Chemical compound C1=C[C]2C(S(=O)(=O)N)=CC=CC2=C=C1 MSPCOXFYKUKYLB-UHFFFAOYSA-N 0.000 description 1
- DASJFYAPNPUBGG-UHFFFAOYSA-N naphthalene-1-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CC=CC2=C1 DASJFYAPNPUBGG-UHFFFAOYSA-N 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- GHCAUEMXBSLMGU-UHFFFAOYSA-N oxadiazole;1,2,5-oxadiazole Chemical compound C=1C=NON=1.C1=CON=N1 GHCAUEMXBSLMGU-UHFFFAOYSA-N 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- CRTBNOWPBHJICM-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1.C1=CN=CC=N1 CRTBNOWPBHJICM-UHFFFAOYSA-N 0.000 description 1
- IOXGEAHHEGTLMQ-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1.C1=CC=NN=C1 IOXGEAHHEGTLMQ-UHFFFAOYSA-N 0.000 description 1
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 1
- YMXFJTUQQVLJEN-UHFFFAOYSA-N pyrimidine Chemical compound C1=CN=CN=C1.C1=CN=CN=C1 YMXFJTUQQVLJEN-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- ZXBMYFJTFBIWGO-UHFFFAOYSA-N quinoxaline-5-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)N)=CC=CC2=N1 ZXBMYFJTFBIWGO-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000012972 squamous cell carcinoma of colon Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 239000004291 sulphur dioxide Substances 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- LBLZPOGZQOBQKC-UHFFFAOYSA-N thiadiazole-4-sulfonamide Chemical compound NS(=O)(=O)C1=CSN=N1 LBLZPOGZQOBQKC-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- WEMNATFLVGEPEW-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1.C=1C=CSC=1 WEMNATFLVGEPEW-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to compounds which act as Lysine Acetyl Transferase (KAT) inhibitors of the MYST family.
- KAT Lysine Acetyl Transferase
- the MYST family is the largest family of KATs and is named after the founding members in yeast and mammals: MOZ, Ybf2/Sas3, Sas2 and TIP60 (Dekker 2014). MYST proteins mediate many biological functions including gene regulation, DNA repair, cell-cycle regulation and development (Avvakumov 2007; Voss 2009). The KAT proteins of the MYST family play key roles in post-translational modification of histones and thus have a profound effect on chromatin structure in the eukaryotic nucleus (Avvakumov 2007).
- the family currently comprises five mammalian KATs: TIP60 (KAT5; HTATIP; MIM 601409), MOZ (KAT6A; MIM 601408; MYST3), MORF (KAT6b; QKF; MYST4), HBO (KAT8; HBO1; MYST2) and MOF (KAT8; MYST1) (Voss 2009).
- TIP60 KAT5; HTATIP; MIM 601409
- MOZ KAT6A; MIM 601408; MYST3
- MORF KAT6b; QKF; MYST4
- HBO KAT8; HBO1; MYST2
- MOF KAT8; MYST1
- MYST proteins function in multisubunit protein complexes including adaptors such as ING proteins that mediate DNA binding (Avvakumov 2007).
- ING proteins that mediate DNA binding
- TIP60 is affiliated to the NuA4 multiprotein complex (which embraces more than 16 members) (Zhang 2017).
- Holbert 2007 there have also been some reports of a helix-turn-helix DNA-binding motif within the structure of the MOZ protein itself (Holbert 2007), which suggests the capacity to bind directly to DNA.
- the acetyltransferase activity of MYST proteins is effected by the MYST domain (the catalytic domain).
- the MYST domain contains an acetyl-coenzyme A binding motif, which is structurally conserved with other HATs, and an unusual C 2 HC-type zinc finger (Voss 2009).
- the highly conserved MYST domain, including the acetyl-CoA binding motif and zinc finger, is considered to be the defining feature of this family of enzymes (Avvakumov 2007).
- HBO1 positively regulates initiation of DNA replication (Avvakumov 2007; Aggarwal 2004; Doyon 2006; Iizuka 2006) via acetylation of histone substrates, which presumably leads to a more accessible chromatin conformation (Avvakumov 2007, Iizuka 2006).
- HBO1 is also known to play a role in the pathogenesis of breast cancer by promoting an enrichment of cancer stem-like cells (Duong 2013) and by destabilising the estrogen receptor ⁇ (ER ⁇ ) through ubiquinitiation, which proceeds via the histone-acetylating activity of HBO1 (Iizuka 2013).
- HBO1 has also been implicated in Acute myeloid leukaemia (AML) (Shi 2015).
- TIP60 (KAT5) is the most studied member of the MYST family. TIP60 plays an important role not only in the regulation of transcription but also in the process of DNA damage repair, particularly in DNA double-strand breaks (DSB) (Gil 2017). TIP60 can acetylate p53, ATM and c-Myc. TIP60 and MOF specifically acetylate lysine 120 (K120) of p53 upon DNA damage (Avvakumov 2007). TIP60 has also been implicated in being important for regulatory T-cell (Treg) biology.
- FOXP3 is the master regulator in the development and function of Tregs and it has been shown that acetylation of FOXP3 by TIP60 is essential for FOXP3 activity (Li 2007, Xiao 2014).
- conditional TIP60 deletion in mice leads to a scurfy-like fatal autoimmune disease, mimicking a phenotype seen in FOXP3 knock out mice (Xiao 2014).
- Treg cells can facilitate tumour progression by suppressing adaptive immunity against the tumour.
- MOF males absent on the first
- MOF was originally identified as one of the components of the dosage compensation in Drosophila , and was classified as a member of the MYST family based on functional studies and sequence analysis (Su 2016).
- the human ortholog exhibits significant similarity to drosophila MOF; containing an acetyl-CoA-binding site, a chromodomain (which binds histones) and a C 2 HC-type zinc finger (Su 2016).
- MOF is a key enzyme for acetylating histone H4K16, and MOF-containing complexes are implicated in various essential cell functions with links to cancer (Su 2016).
- MOF metal-oxide-semiconductor
- a critical role of MOF in tumorigenesis suggests a critical role of MOF in tumorigenesis (Su 2016).
- KAT activity of MOF has been shown to be required to sustain MLL-AF9 leukemia and may be important for multiple AML subtypes (Valerio 2017).
- KAT6B (Querkopf) was first identified in a mutation screen for genes regulating the balance between proliferation and differentiation during embryonic development (Thomas 2000). Mice homozygous for the KAT6B mutant allele have severe defects in cerebral cortex development resulting from a severe reduction in both proliferation and differentiation of specifically the cortical progenitor population during embryonic development. KAT6B is required for the maintenance of the adult neural stem cell population and is part of a system regulating differentiation of stem cells into neurons (Merson 2006). KAT6B is also mutated in rare forms of leukaemia (Vizmanos 2003).
- MOZ locus ranks as the 12th most commonly amplified region across all cancer types (Zack 2013). MOZ is within the 8p11-p12 amplicon, which is seen at frequencies around 10-15% in various cancers, especially breast and ovarian (Turner-Ivey 2014). MOZ was first identified as a fusion partner of the CREB-binding protein (CBP) during examination of a specific chromosomal translocation in acute myeloid leukaemia (AML) (Avvakumov 2007; Borrow 1996). MOZ KAT activity is necessary for promoting the expression of MEIS1 and HOXa9, proteins that are typically seen overexpressed in some lymphomas and leukaemias.
- CBP CREB-binding protein
- Inhibitors of some MYSTs are known.
- the present invention provides compounds which inhibit the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.
- a first aspect of the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in a method of therapy:
- R 1 , R 2 , R 3 and R 4 are independently selected from:
- a first aspect also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined and a pharmaceutically acceptable excipient.
- a second aspect of the present invention provides a method of treatment of cancer, comprising administering to a patient in need of treatment, a compound, or a pharmaceutically acceptable salt thereof, as defined in the first aspect of the invention or a pharmaceutical composition of the first aspect of the invention.
- the second aspect of the present invention also provides the use of a compound, or a pharmaceutically acceptable salt thereof, as defined in the first aspect of the invention in the manufacture of a medicament for treating cancer, and a compound, or a pharmaceutically acceptable salt thereof, as defined in the first aspect of the invention or pharmaceutical composition thereof for use in the treatment of cancer.
- the compound as defined in the first aspect may be administered simultaneously or sequentially with radiotherapy and/or chemotherapy in the treatment of cancer.
- a third aspect of the invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof:
- R 1 , R 2 , R 3 and R 4 are independently selected from:
- R 4 is OMe
- R 4 is Cl, and either R 1 , R 2 and R 3 are H, or R 2 is C 1-3 alkyl or bromo, and R 1 and R 3 are H; or (d) R 3 is C 1-3 alkyl and R 1 , R 2 and R 4 are H.
- a fourth aspect of the present invention provides the synthesis of compounds as defined in the first or third aspects of the invention, as described below.
- substituted refers to a parent group which bears one or more substituents.
- substituted is used herein in the conventional sense and refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent group.
- optionally substituted as used herein, pertains to a parent group which may be unsubstituted or which may be substituted.
- C 5-12 heteroaryl refers to a monovalent moiety obtained by removing a hydrogen atom from an aromatic structure having from 5 to 12 rings atoms, of which from 1 to 3 are ring heteroatoms.
- aromatic structure is used to denote a single ring or fused ring systems having aromatic properties
- ring heteroatom refers to a nitrogen, oxygen or sulphur atom.
- the prefixes denote the number of atoms making up the aromatic structure, or range of number of atoms making up the aromatic structure, whether carbon atoms or heteroatoms.
- C 5-12 heteroaryl structures include, but are not limited to, those derived from:
- N 1 pyrrole (azole) (C 5 ), pyridine (azine) (C 6 ); pyridone (C 6 ); indole (C 9 ); quinoline (C 10 ); S 1 : furan (oxole) (C 5 ); S 1 : thiophene (thiole) (C 5 ); N 1 O 1 : oxazole (C 5 ), isoxazole (C 5 ), isoxazine (C 6 ); N 2 O 1 : oxadiazole (furazan) (C 5 ); N 1 S 1 : thiazole (C 5 ), isothiazole (C 5 ); N 2 S 1 : thiadiazole (C 5 ) N 2 : imidazole (1,3-diazole) (C 5 ), pyrazole (1,2-diazole) (C 5 ), pyridazine (1,2-diazine) (C 6 ), pyr
- Halo refers to a group selected from fluoro, chloro, bromo and iodo.
- Cyano refers to a group —C ⁇ N.
- Hydroxy refers to a group —OH.
- Phenyl the term “phenyl” as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a single aromatic ring structure having 6 carbon ring atoms (—C 6 H 5 ).
- Phenoxy the term “phenoxy” as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from the oxygen atom of phenol (—O—C 6 H 5 ).
- C 1-4 alkyl refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a saturated hydrocarbon compound having from 1 to 4 carbon atoms.
- saturated alkyl groups include, but are not limited to, methyl (C 1 ), ethyl (C 2 ), propyl (C 3 ), and butyl (C 4 ).
- saturated linear alkyl groups include, but are not limited to, methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), and n-butyl (C 4 ).
- saturated branched alkyl groups include iso-propyl (C 3 ), iso-butyl (C 4 ), sec-butyl (C 4 ) and tert-butyl (C 4 ).
- C 3-6 cycloalkyl refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a saturated cyclic hydrocarbon compound having from 3 to 6 carbon atoms.
- Examples of C 3-6 cycloalkyl groups include, but are not limited to, cyclopropyl (C 3 ), cyclobutyl (C 4 ), cyclopentyl (C 5 ) and cyclonexyl (C 6 ).
- C 1-4 alkoxy refers to a monovalent moiety obtained by removing a hydrogen atom from an oxygen atom of a saturated alcohol compound having from 1 to 4 carbon atoms. It can be represented as —O—C 1-4 alkyl. Examples of C 1-4 alkoxy groups include, but are not limited to, methoxy (C 1 ), ethoxy (C 2 ), propyloxy (C 3 ), and butyloxy (C 4 ).
- C 1-4 alkyl carbamoyl —NHC( ⁇ O)OR wherein R is a C 1-4 alkyl group as defined above.
- Examples of C 1-4 alkyl carbamoyl include, but are not limited to, —N(H)C( ⁇ O)OCH 3 , —N(H)C( ⁇ O)OCH 2 CH 3 , and —N(H)C( ⁇ O)OC(CH 3 ) 3 .
- Acylamido —NR(C ⁇ O)R′ wherein R and R′ are independently selected from H and C 1-4 alkyl as defined above. R and R′ may also be —(CH 2 ) n —, where n is 3 or 4.
- Examples of an acylamido group include, but are not limited to, —N(H)C( ⁇ O)CF 3 , N(H)C( ⁇ O)Me, and:
- C 1-4 alkyl ester refers to a monovalent moiety obtained by removing a hydrogen atom from an oxygen atom of a saturated carboxylic acid compound having from 1 to 5 carbon atoms. It can be represented as —O—C(O)—C 1-4 alkyl.
- C 1-4 alkyl ester groups include, but are not limited to, acetoxy (—O—C(O)—CH 3 ), propanoyloxy (—O—C(O)—CH 2 CH 3 ), butanoyloxy (—O—C(O)—CH 2 CH 2 CH 3 ) and pentanoyloxy (—O—C(O)—CH 2 CH 2 CH 2 CH 3 ).
- a reference to carboxylic acid also includes the anionic (carboxylate) form (—COO ⁇ ), a salt or solvate thereof, as well as conventional protected forms.
- a reference to an amino group includes the protonated form (—N + HR 1 R 2 ), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group.
- a reference to a hydroxyl group also includes the anionic form (—O ⁇ ), a salt or solvate thereof, as well as conventional protected forms.
- a salt of the active compound may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt.
- pharmaceutically acceptable salts are discussed in Berge 1977.
- a salt may be formed with a suitable cation.
- suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al +3 .
- Suitable organic cations include, but are not limited to, ammonium ion (i.e. NH 4 +) and substituted ammonium ions (e.g. NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
- suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
- An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
- a salt may be formed with a suitable anion.
- suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
- Suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, trifluoroacetic acid and valeric.
- solvate is used herein in the conventional sense to refer to a complex of solute (e.g. active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
- Certain compounds of the invention may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and I-forms; (+) and ( ⁇ ) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; ⁇ - and ⁇ -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as “isomers” (or “isomeric forms”).
- chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
- stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
- Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
- Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
- the compounds of the invention may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention.
- a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
- a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
- the terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
- the carbon atom to which R 1 and Cy are bound may be a stereochemical centre, i.e. when R 1 is not H and R 1 and Cy are different.
- the compounds of the present invention may be a racemic mixture, or may be in enantiomeric excess or substantially enantiomerically pure.
- isomers are structural (or constitutional) isomers (i.e. isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
- a reference to a methoxy group, —OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, —CH 2 OH.
- a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.
- a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g. C 1-7 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
- C 1-7 alkyl includes n-propyl and iso-propyl
- butyl includes n-, iso-, sec-, and tert-butyl
- methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl
- keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hyroxyazo, and nitro/aci-nitro.
- tautomer or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
- proton tautomers also known as prototropic tautomers
- Valence tautomers include interconversions by reorganization of some of the bonding electrons.
- H may be in any isotopic form, including 1 H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 O and 18 O; and the like.
- isotopes examples include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as, but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl, and 125 I.
- isotopically labeled compounds of the present invention for example those into which radioactive isotopes such as 3H, 13C, and 14C are incorporated.
- Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
- Deuterium labelled or substituted therapeutic compounds of the invention may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
- An 18F labeled compound may be useful for PET or SPECT studies.
- Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
- substitution with heavier isotopes, particularly deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index.
- deuterium in this context is regarded as a substituent.
- the concentration of such a heavier isotope, specifically deuterium may be defined by an isotopic enrichment factor.
- any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
- a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof.
- Methods for the preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.
- the compounds of the present invention inhibit the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.
- the inhibitory activity of the compounds of the invention is likely to vary between the KATs of the MYST family.
- the compounds of the present invention may selectively inhibit the activity of one or more KATs of the MYST family over other KATs of the MYST family, i.e. the inhibitory activity of the compound may be higher for one or more of the KATs of the MYST family over one or more of the other KATs of the MYST family.
- Compounds of the present invention may (selectively) inhbit the activity of a single KAT of the MYST family.
- compounds of the present invention may inhibit the activity of TIP60, MORF, MOZ, HBO1 or MOF.
- Compounds of the present invention may inhibit the activity of two KATs of the MYST family, for example MOZ and MORF.
- Compounds of the present invention may inhibit the activity of three KATs of the MYST family, for example MOZ, MORF and HBO1.
- Compounds of the present invention may inhibit the activity of four KATs of the MYST family, for example MOZ, MORF, HBO1 and TIP60.
- Compounds of the present invention may inhibit the activity of all five KATs of the MYST family, thus the compounds may inhibit the activity of TIP60, MORF, MOZ, HBO1 and MOF.
- Compounds of the present invention may, in particular, inhibit the activity of MOZ and/or KAT6B and/or HBO1 and/or TIP60.
- Compounds disclosed herein may provide a therapeutic benefit in a number of disorders, in particular, in the treatment or prevention of cancers.
- Inhibitors of post-translational lysine acetylation mediated by KATs of the MYST family are considered to be promising anti-neoplastic agents and therefore may be useful therapeutic agents, e.g. for use in the treatment of cancer. Such agents may also be useful as therapeutic agents for the treatment of cancers which exhibit overexpression of MYST proteins.
- a “cancer” may be any form of cancer.
- a cancer can comprise any one or more of the following: leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), non-Hodgkin's lymphoma, Hodgkin's disease, prostate cancer, lung cancer, melanoma, breast cancer, colon and rectal cancer, colon cancer, squamous cell carcinoma and gastric cancer.
- ALL acute lymphocytic leukemia
- AML acute myeloid leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myeloid leukemia
- non-Hodgkin's lymphoma Hodgkin's disease
- prostate cancer lung cancer
- melanoma breast cancer
- colon and rectal cancer colon cancer
- colon cancer squamous cell carcinoma and gastric cancer.
- the cancer may comprise adrenocortical cancer, anal cancer, bladder cancer, blood cancer, bone cancer, brain tumor, cancer of the female genital system, cancer of the male genital system, central nervous system lymphoma, cervical cancer, childhood rhabdomyosarcoma, childhood sarcoma, endometrial cancer, endometrial sarcoma, esophageal cancer, eye cancer, gallbladder cancer, gastrointestinal tract cancer, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hypopharyngeal cancer, Kaposi's sarcoma, kidney cancer, laryngeal cancer, liver cancer, malignant fibrous histiocytoma, malignant thymoma, mesothelioma, multiple myeloma, myeloma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, nervous system cancer, neuroblastoma, oral cavity cancer, oropharyn
- Cancers may be of a particular type.
- types of cancer include lymphoma, melanoma, carcinoma (e.g. adenocarcinoma, hepatocellular carcinoma, medullary carcinoma, papillary carcinoma, squamous cell carcinoma), astrocytoma, glioma, medulloblastoma, myeloma, meningioma, neuroblastoma, sarcoma (e.g. angiosarcoma, chrondrosarcoma, osteosarcoma).
- carcinoma e.g. adenocarcinoma, hepatocellular carcinoma, medullary carcinoma, papillary carcinoma, squamous cell carcinoma
- astrocytoma e.g. adenocarcinoma, hepatocellular carcinoma, medullary carcinoma, papillary carcinoma, squamous cell carcinoma
- astrocytoma e.g. adenocarcinoma,
- the cancer may be a MYST overexpressing cancer.
- the cancer may overexpress MYST protein relative to non-cancerous tissue.
- the cancer overproduces MYST mRNA relative to non-cancerous tissue.
- the overexpressed MYST protein or MYST mRNA may be any one KATs of the MYST family, i.e. any one of TIP60, KAT6B, MOZ, HBO1 and MOF.
- the cancer may overexpress more than one KATs of the MYST family, e.g. two or more selected from the group consisting of TIP60, KAT6B, MOZ, HBO1 and MOF.
- the cancer may be a cancer that evades immune recognition, e.g. via tumor-associated Treg cells.
- the cancer may be a bromodomain overexpressing cancer:
- the cancer cell may overexpress one or more bromodomain-containing proteins (herein referred to as “bromodomain proteins”) relative to non-cancerous tissue. It may overproduce one or more bromodomain mRNA as compared to non-cancerous tissue.
- the level of bromodomain protein and/or mRNA in the cell is at a level approximately equivalent to that of a non-cancerous cell.
- the cancer may overexpress one or more bromodomain proteins selected from the group consisting of; a bromodomain protein (namely BRD2, BRD3, BRD4, BRD7, BRD8, BRD9 and BRDT), TAF1/TAF1L, TFIID, SMARC2 (also called BRM) and SMARC4 (also called BRG1).
- a bromodomain protein namely BRD2, BRD3, BRD4, BRD7, BRD8, BRD9 and BRDT
- TAF1/TAF1L TFIID
- SMARC2 also called BRM
- SMARC4 also called BRG1
- some colon cancers overexpress BRD8.
- Some acute myeloid leukemia cells overexpress BRD4.
- Treg cells are immunosuppressive cells, which act to prevent autoimmunity in the healthy mammalian immune system.
- some cancers act to upregulate Treg activity to evade the host immune system.
- Infiltration of Tregs in many tumour types correlates with poor patient prognoses and Treg cell depletion in tumour models demonstrates increased anti-tumour immune responses (Melero 2015).
- Tumour-associated Treg suppression of the host immune system has been reported in lung (Joshi 2015), (Tso 2012), breast (Gobert 2009; Yan 2011), prostate (Miller 2006) & pancreatic (Wang X 2016) cancers.
- FOXP3 is considered to be the master regulator of Treg differentiation, development and function of Treg cells.
- FOXP3 acetylation of FOXP3 plays a critical role in the stability of the FOXP3 protein and in regulating its ability to access DNA; and FOXP3 acetylation is mediated by KATs (Dhuban 2017). Decreases in TI P60-mediated FOXP3 acetylation has been shown to attenuate Treg development, suggesting a further mechanism by which the inhibition of the acetylating activity of MYST proteins could be used to intervene in diseases such as cancer.
- the agents described herein may be useful in combination with other anti-cancer therapies. They may act synergistically with chemo- or radiotherapy, and/or with targeted therapies, including but not limited to FGFR1 inhibitors and therapies targeting nuclear hormone receptors.
- the agents described herein may be useful in combination with bromodomain targeted drugs including BET inhibitors.
- BET inhibitors reversibly bind the bromodomains of the BET proteins BRD2, BRD3, BRD4 and BRDT.
- a MYST protein antagonist disclosed herein may be administered in conjunction with a radiotherapeutic or chemotherapeutic regime. It may be administered simultaneously or sequentially with radio and/or chemotherapy. Suitable chemotherapeutic agents and radiotherapy protocols will be readily appreciable to the skilled person.
- the compound described herein may be combined with low dose chemo or radio therapy. Appropriate dosages for “low dose” chemo or radio therapy will be readily appreciable to the skilled practitioner.
- the compounds of the present application are used to abrogate Treg suppression, these may be combined with with immune checkpoint inhibitors (Melero 2015, Wang L 2016). Furthermore, where compounds of the present invention which abrogate Treg suppression may be used in combination with radiotherapy, to reduce the depletion of Treg function in tumours (Persa 2015, Jeong 2016)
- the compounds of the present invention may be used in a method of therapy. Also provided is a method of treatment, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of the invention.
- a therapeutically-effective amount is an amount sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom.
- the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors.
- the anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy.
- Such chemotherapy may include one or more of the following categories of anti-tumour agents:—
- antiproliferative/antineoplastic drugs and combinations thereof as used in medical oncology, such as alkylating agents (for example cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5 fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine
- inhibitors of growth factor function include growth factor antibodies and growth factor receptor antibodies (for example the anti erbB2 antibody trastuzumab [HerceptinT], the anti-EGFR antibody panitumumab, the anti erbB1 antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibodies disclosed by Stern 2005; such inhibitors also include tyrosine kinas
- the active compound or pharmaceutical composition comprising the active compound may be administered to a subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g. transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an aerosol, e.g.
- vaginal parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, intravitreal and intrasternal; by implant of a depot, for example, subcutaneously, intravitreal or intramuscularly.
- the subject may be a eukaryote, an animal, a vertebrate animal, a mammal, a rodent (e.g.
- a guinea pig, a hamster, a rat, a mouse murine (e.g. a mouse), canine (e.g. a dog), feline (e.g. a cat), equine (e.g. a horse), a primate, simian (e.g. a monkey or ape), a monkey (e.g. marmoset, baboon), an ape (e.g. gorilla, chimpanzee, orang-utan, gibbon), or a human.
- simian e.g. a monkey or ape
- a monkey e.g. marmoset, baboon
- an ape e.g. gorilla, chimpanzee, orang-utan, gibbon
- a human e.g. gorilla, chimpanzee, orang-utan, gibbon
- the active compound While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g. formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
- a pharmaceutical composition e.g. formulation
- the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilisers, or other materials, as described herein.
- pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- a subject e.g. human
- Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
- Formulations may be in the form of liquids, solutions, suspensions, emulsions, elixirs, syrups, tablets, losenges, granules, powders, capsules, cachets, pills, ampoules, suppositories, pessaries, ointments, gels, pastes, creams, sprays, mists, foams, lotions, oils, boluses, electuaries, or aerosols.
- Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as a bolus; as an electuary; or as a paste.
- a tablet may be made by conventional means, e.g., compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g. povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g. lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc, silica); disintegrants (e.g.
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
- Formulations suitable for topical administration may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol, or oil.
- a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active compounds and optionally one or more excipients or diluents.
- Formulations suitable for topical administration in the mouth include losenges comprising the active compound in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active compound in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active compound in a suitable liquid carrier.
- Formulations suitable for topical administration to the eye also include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active compound.
- Formulations suitable for nasal administration wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser include aqueous or oily solutions of the active compound.
- Formulations suitable for administration by inhalation include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- Formulations suitable for topical administration via the skin include ointments, creams, and emulsions.
- the active compound When formulated in an ointment, the active compound may optionally be employed with either a paraffinic or a water-miscible ointment base.
- the active compounds may be formulated in a cream with an oil-in-water cream base.
- the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
- the topical formulations may desirably include a compound which enhances absorption or penetration of the active compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
- the oily phase may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
- an emulsifier otherwise known as an emulgent
- a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
- the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate.
- the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low.
- the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required.
- mono-isoadipate such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the
- high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound, such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions which may contain anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
- Suitable isotonic vehicles for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
- concentration of the active compound in the solution is from about 1 ng/mL to about 10 ⁇ g/mL, for example from about 10 ng/ml to about 1 ⁇ g/mL.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
- Formulations may be in the form of liposomes or other microparticulate systems which are designed to target the active compound to blood components or one or more organs.
- appropriate dosages of the compound, and compositions comprising the compound can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects.
- the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the patient.
- the amount of compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
- a suitable dose of the active compound is in the range of about 100 ng to about 25 mg (more typically about 1 ⁇ g to about 10 mg) per kilogram body weight of the subject per day.
- the active compound is a salt, an ester, an amide, a prodrug, or the like
- the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
- the active compound is administered to a human patient according to the following dosage regime: about 100 mg, 3 times daily.
- the active compound is administered to a human patient according to the following dosage regime: about 150 mg, 2 times daily.
- the active compound is administered to a human patient according to the following dosage regime: about 200 mg, 2 times daily.
- the active compound is administered to a human patient according to the following dosage regime: about 50 or about 75 mg, 3 or 4 times daily.
- the active compound is administered to a human patient according to the following dosage regime: about 100 or about 125 mg, 2 times daily.
- treatment pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, regression of the condition, amelioration of the condition, and cure of the condition.
- Treatment as a prophylactic measure i.e., prophylaxis, prevention is also included.
- terapéuticaally-effective amount pertains to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
- prophylactically-effective amount refers to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired prophylactic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
- the subject/patient may be an animal, mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a monotreme (e.g., duckbilled platypus), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an
- the subject/patient may be any of its forms of development, for example, a foetus.
- the subject/patient is a human.
- the compounds of the invention can be prepared by employing the following general methods and using procedures described in detail for the examples.
- the reaction conditions referred to are illustrative and non-limiting, for example one skilled in the art may use a diverse range of synthetic methods to synthesise the desired compounds such as but not limited to methods described in literature (for example but not limited to March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition or Larock's Comprehensive Organic Transformations: Comprehensive Organic Transformations: A Guide to Functional Group Preparations).
- Scheme 1A illustrates the formation of a sulfonamide bond to form compounds with the structure I by coupling a relevant sulfonyl chloride compound of structure G2 with a primary or secondary amine such as benzisoxazole amine G3.
- sulfonamides will be apparent to those skilled in the art, but include for example the use of a suitable base such as but not limited to pyridine, LiHMDS, n-BuLi or NaH and the use of activated forms of the sulfonic acid such as the corresponding sulfonyl halide.
- a suitable base such as but not limited to pyridine, LiHMDS, n-BuLi or NaH
- activated forms of the sulfonic acid such as the corresponding sulfonyl halide.
- Formation of sulfonyl chlorides of structure G2 from the corresponding acids of structure G1 can be achieved by for example use of thionyl chloride or cyanuric chloride.
- the activated form of a sulfonic acid such as but not limited to a pentafluorophenyl sulfonate ester or trichlorophenyl sulfonate ester with the structure G5 can be coupled with the relevant primary or secondary amine, such as benzisoxazole amine G3 (Scheme 1B).
- Formation of the sulfonate ester in G5 from the corresponding sulfonyl chloride G2 and relevant phenol (R 5 may be for example pentaflurorphenyl or trichlorophenyl) can be achieved using a suitable base such as but not limited to pyridine or triethylamine.
- a suitable base such as but not limited to pyridine or triethylamine.
- Scheme 2A illustrates the formation of a sulfonyl chloride such as G2, as a substituent which is part of Ar.
- aryl compound G6 may be sequentially treated with a base, such as but not limited to n-BuLi, and sulphur dioxide to furnish the lithium arylsulfinate which is further oxidised by for example sulfuryl chloride to give the desired sulfonyl chloride in G2.
- a base such as but not limited to n-BuLi
- sulphur dioxide to furnish the lithium arylsulfinate which is further oxidised by for example sulfuryl chloride to give the desired sulfonyl chloride in G2.
- the product G2 may be isolated by methods know to those skilled in the art or may be formed in situ and used immediately in subsequent step.
- the sulfonyl chloride in G2 may be formed from an aryl thiol in structure G8 illustrated in Scheme 2B.
- Methods to form G2 include for example the use of a suitable oxidant such as but not limited to hydrogen peroxide and potassium nitrate in the presence of a chloride source such as but not limited to chlorotrimethylsilane or thionyl chloride.
- a thiol of structure G8 may be synthesised from a compound of structure G7 where (X) may be a halogen by methods known to those skilled in the art, including but not limited to nucleophilic displacement in the presence or absence of a transition metal.
- sulfonation of an aryl compound such as G6 may give the corresponding sulfonic acid of structure G1. This can be achieved by any suitable reagent known to those skilled in the art, for example sulphur trioxide or sulfuric acid.
- the sulfonic acid G1 may be converted to the sulfonyl chloride G2 by methods outlined in General Synthesis 1, Scheme 1A.
- Scheme 3A illustrates the formation of a benzisoxazole amine such as G3 from an aryl nitrile with an ortho substituent X, such as structure G9.
- the group (X) may be, but is not limited to, a halogen such as a chloro or a fluoro group and is chosen to be suitable for the reaction employed.
- the starting material G9 may be reacted with an oxime such as but not limited to acetone oxime or with for example acetohydroxamic acid, in the presence of a suitable base such as but not limited to potassium tert-butoxide, to form the benzisoxazole amine G3.
- an oxime such as but not limited to acetone oxime or with for example acetohydroxamic acid
- a suitable base such as but not limited to potassium tert-butoxide
- Scheme 4A illustrates the addition of an R 7 group to a compound of structure G10 (where R 6 represents H or a suitable protecting group including but not limited to 2,4-dimethoxybenzyl (DMB); methods for the removal of said protecting groups will be known to those skilled in the art (for example Greene's Protective Groups in Organic Synthesis, 4 th Edition )), as a substituent which is part of Ar.
- R 6 represents H or a suitable protecting group including but not limited to 2,4-dimethoxybenzyl (DMB); methods for the removal of said protecting groups will be known to those skilled in the art (for example Greene's Protective Groups in Organic Synthesis, 4 th Edition )), as a substituent which is part of Ar.
- This can be achieved using any suitable coupling reaction known to the person skilled in the art, for example Suzuki coupling.
- the groups R 7 B 1 and X are chosen to be suitable for the coupling reaction employed.
- (X) may be a halogen, triflate or other suitable group
- Examples of B 1 that can be used in the Suzuki coupling include, but are not limited to, those shown below.
- a variety of coupling reactions may be used to introduce the R 7 group other than Suzuki coupling, such as for example transition metal catalysed coupling reactions or for example tin (Stille type reaction) and zinc (Negishi type reaction) compounds.
- a Chan-Lam type coupling may be used when the group (X) is for example, but not limited to, a phenol (O—H) or primary or secondary amine (R′R′′N—H).
- substituent R 7 may be introduced prior to sulfonamide and benzisoxazole formation on the nitrile precursor G9 (when R 1 or R 2 or R 3 or R 4 ⁇ X or B 1 ) in General Synthesis 3, Scheme 3D.
- Scheme 5A illustrates the addition of a nitrogen linked R 8 group, as a substituent which is part of Ar or on the benzisoxazole moiety to give a compound of structure G16.
- This can be achieved using any suitable coupling reaction known to the person skilled in the art, for example, by SnAr displacement or Buchwald coupling.
- the group denoted by (X) may be, but not limited to, a halogen and is chosen to be suitable for the coupling reaction employed.
- substituent OR 8 or NHR 8 may be introduced prior to sulfonamide and benzisoxazole formation on the nitrile precursor G9 (when R 1 or R 2 or R 3 or R 4 ⁇ X) in General Synthesis 3, Scheme 3D.
- Scheme 6A illustrates the addition of an amine (HNR 10 R 11 )) to form the corresponding amide, as a substituent which is a part of Ar or on the benzisoxazole moiety to give a compound of structure G19.
- This can be achieved by coupling a relevant carboxylic acid with a primary amine or a secondary amine NHR 10 R 11 .
- Methods to form such amides will be apparent to those skilled in the art, but include for example the use of reagents such as HATU, HBTU, T3P and EDCl/HOBt, and the use of activated forms of the carboxylic acid such as the corresponding acyl halide, mixed anhydride or N-hydroxysuccinimide ester.
- a base such as an alkali metal hydroxide or an acid for example aqueous hydrochloric acid.
- the ester or acid G18 in Scheme 7A may be reduced to the hydroxyl compound such as structure G21.
- Methods for such transformation will be known to those skilled in the art but include for example the use of reducing agents such as lithium aluminium hydride (for the ester and carboxylic acid) and borane (for the carboxylic acid).
- an ester group may be introduced prior to sulfonamide and benzisoxazole formation on the nitrile precursor G9 (when R 1 or R 2 or R 3 or R 4 ⁇ X) in General Synthesis 3, Scheme 3D.
- Scheme 8A illustrates the reduction of a nitro group in structure G22 to form the corresponding amine in structure G23, as a substituent which is part of the Ar or on the benzisoxazole moiety.
- Reduction of the nitro group to the primary amine G23 will be apparent to those skilled in the art and include but are not limited to using reducing conditions such as a transition metal (Fe, In, Zn) in the presence of HCl, hydrogenation in the presence of a transition metal or transition metal catalyst.
- reducing conditions such as a transition metal (Fe, In, Zn) in the presence of HCl, hydrogenation in the presence of a transition metal or transition metal catalyst.
- an amine group may be introduced prior to sulfonamide and benzisoxazole formation on the nitrile precursor G9 (when R 1 or R 2 or R 3 or R 4 ⁇ NO 2 ) in General Synthesis 3, Scheme 3D.
- Scheme 9A illustrates the introduction of a nitrile group in structure G25, as a substituent which is part or the Ar or on the benzisoxazole moiety.
- the method for such transformation will be apparent to those skilled in the art and include but are not limited to SnAr displacement, or a transition metal catalysed coupling with a suitable cyanide reagent.
- the group denoted by (X) in structure G24 may be, but not limited to, a halogen, triflate or mesylate and is chosen to be suitable for the reaction employed.
- At least one of R 1 , R 2 , R 3 and R 4 may be H. In some of these embodiments, one of R 1 , R 2 , R 3 and R 4 are H. In other of these embodiments, two of R 1 , R 2 , R 3 and R 4 are H. In other of these embodiments, three of R 1 , R 2 , R 3 and R 4 are H.
- At least one of R 1 , R 2 , R 3 and R 4 is not H.
- At least one of R 1 , R 2 , R 3 and R 4 may be C 1-3 alkyl, optionally substituted by:
- phenyl C 5-6 heteroaryl, C 1-4 alkyl carbamoyl, acylamido, or one or more fluoro groups.
- R 1 , R 2 , R 3 and R 4 may be C 1-3 alkyl.
- the C 1-3 alkyl group may be methyl, ethyl or propyl. These groups may be unsubstituted. These groups may be substituted by one or more fluoro groups, and may be perfluorinated, e.g. CF 3 , C 2 F 5 . These groups may be substituted by one, two, three, four or five fluoro groups. In some embodiment, these groups may be substituted by one; one or two; or one, two or three fluoro groups.
- the substituent may be selected from:
- R 1 , R 2 , R 3 and R 4 may be C 1-3 alkoxy, optionally substituted by C 3-6 cycloalkyl or by one of more fluoro groups.
- the C 1-3 alkoxy group may be methoxy, ethoxy or propyloxy. These groups may be unsubstituted. These groups may be substituted by one or more fluoro groups, and may be perfluorinated, e.g. OCF 3 , OC 2 F 5 . These groups may be substituted by one, two, three, four or five fluoro groups. In some embodiment, these groups may be substituted by one; one or two; or one, two or three fluoro groups.
- the alkoxy group may be substituted by C 3-6 cycloalkyl, e.g. cyclopropyl. Thus the overall group may be OCH 2 (cyclopropyl).
- R 1 , R 2 , R 3 and R 4 may be C 3-6 cycloalkyl.
- the C 3-6 cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- the C 3-6 cycloalkyl group may be cyclopropyl.
- At least one of R 1 , R 2 , R 3 and R 4 may be halo.
- the halo group may be fluoro, chloro, bromo or iodo.
- R 1 , R 2 , R 3 and R 4 may be COR C , where R C is selected from NR N1 R N2 , where R N1 and R N2 are independently selected from H and methyl.
- the group may be selected from C(O)NH 2 , C(O)NHCH 3 and C(O)N(CH 3 ) 2 .
- At least one of R 1 , R 2 , R 3 and R 4 may be cyano, NH 2 , NO 2 . In some of these embodiments at least one of R 1 , R 2 , R 3 and R 4 may be cyano. In others of these embodiments at least one of R 1 , R 2 , R 3 and R 4 may be NH 2 . In others of these embodiments at least one of R 1 , R 2 , R 3 and R 4 may be NO 2 .
- At least one of R 1 , R 2 , R 3 and R 4 may be phenyl or C 5-6 heteroaryl, which groups are optionally substituted by methyl, cyano, hydroxy or methoxy. In some of these embodiments at least one of R 1 , R 2 , R 3 and R 4 may be phenyl. In others of these embodiments at least one of R 1 , R 2 , R 3 and R 4 may be C 5-6 heteroaryl, for example oxazolyl, pyrazolyl, triazolyl, pyridyl and pyrimidinyl. The phenyl or C 5-6 heteroaryl group may be unsubstituted.
- the phenyl group may be substituted by methyl, cyano or methoxy.
- the C 5-6 heteroaryl group may be substituted by one or more methyl groups, such that the overall group is, for example, dimethylpyrazolyl or N-methylpyrazolyl.
- R 4 is methoxy
- R 4 is methoxy
- R 2 is CH 2 OCH 3 or CH 2 OCH 2 CH 3 and R 1 and R 3 are H.
- R 4 is methoxy
- R 2 is phenyl, optionally substituted by methyl or methoxy
- R 1 and R 3 are H.
- R 4 is methoxy
- R 2 is C 5-6 heteroaryl, optionally substituted by methyl.
- R 4 is methoxy and R 1 , R 2 and R 3 are H.
- R 4 is chloro
- R 2 is C 1-3 alkyl or bromo
- R 1 and R 3 are H.
- R 4 is chloro and R 1 , R 2 and R 4 are H.
- R 3 is C 1-3 alkyl and R 1 , R 2 and R 4 are H.
- Ar is selected from phenyl, napthyl and C 5-10 heteroaryl groups, which may be unsubstituted or substituted.
- Ar is phenyl
- Ar is napthyl
- Ar is a C 5-10 heteroaryl group.
- the C 5-10 heteroaryl group may be selected from: quinolinyl, benzothiazolyl, quinoxalinyl, benzooxadiazolyl, benzothiadiazolyl, benzofuran and benzotriazolyl.
- Ar is quinolinyl or benzothiazolyl.
- Ar is the group:
- a substituent for Ar is C 1-4 alkyl, optionally substituted by hydroxy, C 1-2 alkoxy, NH 2 , C 1-4 alkyl carbamoyl, or by one or more fluoro groups.
- the C 1-4 alkyl group may be methyl, ethyl, propyl or butyl. These groups may be unsubstituted. These groups may be substituted by one or more fluoro groups, and may be perfluorinated, e.g. CF 3 , C 2 F 5 . If the alkyl group is substituted, the substituent may be selected from:
- a substituent for Ar is C 3-6 cycloalkyl.
- the C 3-6 cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- the C 3-6 cycloalkyl group may be cyclohexyl.
- a substituent for Ar is hydroxy; cyano; NR N3 R N4 , where R N3 and R N4 are independently selected from H and methyl; or acylamido.
- the substituent may be hydroxy.
- the substituent may be cyano.
- the substituent may be NR N3 R N4 , where R N3 and R N4 are independently selected from H and methyl—thus the substituent may be NH 2 , NHCH 3 or N(CH 3 ) 2 .
- the substituent may be acylamido, such as NHCO 2 CH 3 .
- a substituent for Ar is halo.
- the halo group may be fluoro, chloro, bromo or iodo.
- a substituent for Ar is C 1-3 alkoxy, optionally substituted by hydroxy, C(O)NH 2 , C 3-6 cycloalkyl, phenyl, C 5-6 heteroaryl, or by one of more fluoro groups.
- the C 1-3 alkoxy group may be methoxy, ethoxy or propyloxy. These groups may be unsubstituted. These groups may be substituted by one or more fluoro groups, and may be perfluorinated, e.g. OCF 3 , OC 2 F 5 .
- the alkoxy group may be substituted by hydroxyl, such that the overall group is, for example, OC 2 H 4 OH.
- the alkoxy group may be substituted by C(O)NH 2 , such that the overall group is, for example, OCH 2 C(O)NH 2 .
- the alkoxy group may be substituted by C 3-6 cycloalkyl, e.g. cyclopropyl, such that overall group may be, for example, OCH 2 (cyclopropyl).
- the alkoxy group may be substituted by phenyl, such that the overall group is, for example, benzyloxy.
- the alkoxy group may be substituted by C 5-6 heteroaryl, e.g. pyridyl, pyrazolyl, such that the overall group is, for example, OCH 2 (N-methylpyrazolyl) or OCH 2 (methoxypyridyl).
- a substituent for Ar is phenoxy, optionally substituted by fluoro. In some of these embodiments the substituent may be phenoxy. In others of these embodiments, the substituent may be OC 6 H 4 F.
- a substituent for Ar is phenyl or C 5-6 heteroaryl. In some of these embodiments, the substituent is phenyl. In others of these embodiments, the substituent may be C 5-6 heteroaryl, such as oxazolyl or N-pyrazolyl.
- a substituent for Ar is SF 5 or SO 2 CH 3 . In some of these embodiments, the substituent is SF 5 . In others of these embodiments, the substituent is SO 2 Me.
- a substituent for Ar is —(CH 2 ) n —Y—, where Y is O or CH 2 , and n is 2 or 3.
- This substituent is particularly relevant when Ar is phenyl, and forms a partially unsaturated fused ring with the phenyl.
- Ar can be tetralinyl (i.e. fused cyclohexane), indanyl (i.e. fused cyclopentane), chromanyl (i.e. fused tetrahydopyran) or dihydrobenzofuranyl.
- a substituted for Ar is C 1-4 alkyl ester.
- the substituent is C(O)OCH 3 .
- the substituent is C(O)OC(CH 3 ) 3 .
- Ar-1 Certain embodiments of Ar may be represented by the formula (Ar-1):
- R A1 , R A2 , R A3 , R A4 (if present) and R A5 (if present) are independently selected from H and the optional substituents for Ar.
- R A2 is ethyl
- R A3 is selected from cycloalkyl; phenoxy; phenyl; C 5-6 heteroaryl; SF 5 ; and SO 2 CH 3 .
- Ar is 5-ethyl-2-methoxyphenyl.
- Ar is 5-CF 3 -2-methoxyphenyl.
- Ar is 2,6-dimethoxyphenyl.
- Ar is quinolinyl. These compounds may show selective activity against HBO1.
- R 4 is methoxy
- R 2 is selected from CH 2 O CH 3 , CH 2 O CH 2 CH 3 and optionally substituted phenyl
- Ar is 2,6-dimethoxybenzene. These compounds may show particular activity against MOZ and MORF. Compounds where R 2 is selected from CH 2 OCH 3 and CH 2 OCH 2 CH 3 may show selective activity against MOZ and MORF.
- Ar is not 4-aminophenyl.
- Ar is not 2,4,6-trimethylphenyl.
- Ar is not 2-(difluromethoxy)phenyl.
- Ar is not 4-fluoro-3-methyl-phenyl.
- Ar is not unsubstituted napthyl.
- Compounds of particular interest include those of the examples.
- ether lithium bis(trimethylsilyl)amide (LHMDS or LiHMDS), potassium bis(trimethylsilyl)amide (KHMDS), sodium bis(trimethylsilyl)amide (NaHMDS), n-butyllithium (n-BuLi), N-bromosuccinimide (NBS), N-chlorosuccinimide (NCS), pyridinium p-toluenesulfonate (PPTS), azobisisobutyronitrile (AIBN), tetramethylethylenediamine (TMEDA), tert-butyldimethylsilyl chloride (TBSCI), tetra-n-butylammonium fluoride (TBAF), and diisopropyl azodicarboxylate (DIAD).
- LHMDS or LiHMDS lithium bis(trimethylsilyl)amide
- KHMDS potassium bis(trimethylsilyl)amide
- NaHMDS sodium bis(trimethylsilyl)amide
- TLC refers to thin layer chromatography
- LCMS data was generated using either an Agilent 6100 Series Single Quad (LCMS-A), an Agilent 1260 Infinity Series UPLC/MS (LCMS-B), an Agilent 1200 (LCMS-C and LCMS-D), a Waters 2695 alliance (LCMS-E), an Agilent 6120 Single Quad (LCMS-F) or mass-directed HPLC-MS.
- Chlorine isotopes are reported as 35 Cl
- Bromine isotopes are reported as either 79 Br or 81 Br or both 79 Br/ 81 Br.
- Drying gas temp 300° C.
- Vaporizer temperature 200° C.
- Step size 0.1 sec
- Drying gas temp 350° C.
- Step size 0.1 sec
- Nebulizer pressure 35 psi Drying gas temperature: 350° C.
- the sample was dissolved in methanol, the concentration about 0.11-1 mg/mL, then filtered through syringe filter with 0.22 ⁇ m. (Injection volume: 1-10 ⁇ L)
- Nebulizer pressure 35 psi Drying gas temperature: 350° C.
- the sample was dissolved in methanol, the concentration about 0.11-1 mg/mL, then filtered through the syringe filter with 0.22 ⁇ m. (Injection volume: 1-10 ⁇ L)
- Drying gas flow 600 L/hr Cone: 50 L/hr
- Source temperature 100° C.
- the sample was dissolved in methanol, the concentration about 0.11-1 mg/mL, then filtered through the syringe filter with 0.22 ⁇ m. (Injection volume: 1-10 ⁇ L)
- Drying gas temp 250° C.
- Vaporizer temperature 200° C.
- Step size 0.1 sec
- Ion Source Single-quadrupole
- Analytical thin-layer chromatography was performed on Merck silica gel 60 F254 aluminium-backed plates which were visualised using fluorescence quenching under UV light or a basic KMnO 4 dip or Ninhydrin dip.
- Preparative thin-layer chromatography was performed using Tklst (China), grand grade: (HPTLC): 8 ⁇ 2 ⁇ m>80%; (TLC): 10-40 ⁇ m. Type: GF254. Compounds were visualised by UV (254 nm).
- Microwave irradiation was achieved using a CEM Explorer SP Microwave Reactor. Where necessary, anhydrous solvents were purchased from Sigma-Aldrich or dried using conventional methods.
- n-BuLi 2.5 M solution in hexanes, 2.9 mL, 7.32 mmol
- Tributylchlorostannane (1.96 mL, 7.25 mmol) was then added and the mixture was allowed to warm to RT and stirred for 1 h. The solvent was removed under reduced pressure and residue was taken up in hexanes (50 mL).
- the solid was suspended in n-hexane (100 mL), cooled to 0° C. and a solution of SO 2 Cl 2 (4.9 g, 36 mmol) in n-hexane (20 mL) was added dropwise while keeping the internal temperature below 3° C. The mixture was then stirred at 0° C. for 1 h and the solids were collected by filtration and washed with cold n-hexane. The solids were then partitioned between diethyl ether and water, the layers were separated and the aqueous layer was further extracted with diethyl ether.
- the solid was suspended in n-hexane (40 mL), cooled to 0° C. and a solution of SO 2 Cl 2 (634 mg, 4.7 mmol) in n-hexane (5 mL) was added dropwise while keeping the internal temperature below 3° C. The mixture was then stirred at 0° C. for 1 h and the solids were collected by filtration and washed with cold n-hexane. The solids were then partitioned between diethyl ether and water, the layers were separated and the aqueous layer was further extracted with diethyl ether. The combined organic extracts were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give the title compound (590 mg, 40%) as a white solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/392,356 US20220153710A1 (en) | 2018-06-20 | 2021-08-03 | Compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1810092.5 | 2018-06-20 | ||
GBGB1810092.5A GB201810092D0 (en) | 2018-06-20 | 2018-06-20 | Compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/392,356 Continuation US20220153710A1 (en) | 2018-06-20 | 2021-08-03 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200039945A1 true US20200039945A1 (en) | 2020-02-06 |
Family
ID=63042663
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/446,868 Abandoned US20200039945A1 (en) | 2018-06-20 | 2019-06-20 | Compounds |
US17/392,356 Pending US20220153710A1 (en) | 2018-06-20 | 2021-08-03 | Compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/392,356 Pending US20220153710A1 (en) | 2018-06-20 | 2021-08-03 | Compounds |
Country Status (39)
Country | Link |
---|---|
US (2) | US20200039945A1 (zh) |
EP (2) | EP3810602B1 (zh) |
JP (2) | JP2021529738A (zh) |
KR (1) | KR20210022655A (zh) |
CN (1) | CN112334466A (zh) |
AR (1) | AR114972A1 (zh) |
AU (1) | AU2019289888A1 (zh) |
BR (1) | BR112020025869A2 (zh) |
CA (1) | CA3101238A1 (zh) |
CL (1) | CL2020003219A1 (zh) |
CO (1) | CO2020014586A2 (zh) |
CR (1) | CR20210032A (zh) |
CU (1) | CU20200096A7 (zh) |
DK (1) | DK3810602T3 (zh) |
DO (1) | DOP2020000249A (zh) |
EA (1) | EA202092451A1 (zh) |
EC (1) | ECSP20075270A (zh) |
ES (1) | ES2967983T3 (zh) |
FI (1) | FI3810602T3 (zh) |
GB (1) | GB201810092D0 (zh) |
GE (1) | GEP20227403B (zh) |
HR (1) | HRP20231467T1 (zh) |
HU (1) | HUE064744T2 (zh) |
IL (1) | IL279554B1 (zh) |
LT (1) | LT3810602T (zh) |
MA (1) | MA52948B1 (zh) |
MD (1) | MD3810602T2 (zh) |
MX (1) | MX2020012723A (zh) |
NI (1) | NI202000092A (zh) |
PE (1) | PE20210181A1 (zh) |
PH (1) | PH12020500673A1 (zh) |
PL (1) | PL3810602T3 (zh) |
PT (1) | PT3810602T (zh) |
RS (1) | RS64932B1 (zh) |
SG (1) | SG11202010450VA (zh) |
SI (1) | SI3810602T1 (zh) |
TW (1) | TWI826471B (zh) |
UY (1) | UY38270A (zh) |
WO (1) | WO2019243491A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11492346B2 (en) | 2019-06-18 | 2022-11-08 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3471271A1 (en) | 2017-10-16 | 2019-04-17 | Acoustical Beauty | Improved convolutions of digital signals using a bit requirement optimization of a target digital signal |
US20220251075A1 (en) * | 2019-06-19 | 2022-08-11 | Pfizer Inc. | Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives |
US12012373B2 (en) | 2019-07-12 | 2024-06-18 | Canopy Growth Corporation | Cannabinoid derivatives |
WO2022013369A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Kat6 inhibitor methods and combinations for cancer treatment |
AU2022278733A1 (en) * | 2021-05-21 | 2023-11-30 | Aurigene Oncology Limited | Fused isoxazolyl compounds as kat6a inhibitors |
WO2023280182A1 (zh) * | 2021-07-05 | 2023-01-12 | 杭州英创医药科技有限公司 | 作为kat6抑制剂的化合物 |
CA3228411A1 (en) | 2021-08-10 | 2023-02-16 | Xiaomin Zhang | Sulfonamide derivative, preparation method therefor and medical use thereof |
PE20241355A1 (es) | 2021-11-16 | 2024-07-03 | Insilico Medicine Ip Ltd | Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos |
EP4448109A1 (en) * | 2021-12-13 | 2024-10-23 | Aurigene Oncology Limited | Fused benzoisoxazolyl compounds as kat6a inhibitors |
US20230303580A1 (en) | 2022-03-28 | 2023-09-28 | Isosterix, Inc. | Inhibitors of the myst family of lysine acetyl transferases |
US20230416240A1 (en) * | 2022-06-16 | 2023-12-28 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
WO2024201334A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof |
WO2024217563A1 (en) * | 2023-04-19 | 2024-10-24 | Insilico Medicine Ip Limited | Lysine acetyltransferase 6a (kat6a) inhibitor, combinations and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8541588B2 (en) * | 2009-01-12 | 2013-09-24 | Pfizer Limited | Sulfonamide derivatives |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ES2194181T3 (es) | 1996-02-13 | 2003-11-16 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de vegf. |
DK0885198T3 (da) | 1996-03-05 | 2002-03-25 | Astrazeneca Ab | 4-Anilinoquinazolinderivater |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
NZ337750A (en) | 1997-02-12 | 2001-08-31 | Univ Michigan | Protein markers for lung cancer and use thereof |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
RU2262935C2 (ru) | 1999-02-10 | 2005-10-27 | Астразенека Аб | Производные хиназолина в качестве ингибиторов ангиогенеза |
NZ518028A (en) | 1999-11-05 | 2004-03-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
UA73976C2 (uk) | 2000-02-15 | 2005-10-17 | Суджен, Інк. | Заміщені піролом 2-індолінони, фармацевтична композиція, спосіб модуляції каталітичної активності протеїнкінази та спосіб лікування або профілактики захворювання, пов'язаного з протеїнкіназою |
US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AU6623201A (en) | 2000-07-07 | 2002-02-05 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
BR112015023397A2 (pt) * | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
US10065972B2 (en) * | 2014-04-23 | 2018-09-04 | Mitsubishi Tanabe Pharma Corporation | Bicyclic or tricyclic heterocyclic compound |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
US20220267260A1 (en) * | 2016-11-29 | 2022-08-25 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
SI3986890T1 (sl) * | 2019-06-18 | 2024-03-29 | Ctxt Pty Ltd | Derivati benzisoksazol sulfonamida |
-
2018
- 2018-06-20 GB GBGB1810092.5A patent/GB201810092D0/en not_active Ceased
-
2019
- 2019-06-20 SI SI201930674T patent/SI3810602T1/sl unknown
- 2019-06-20 SG SG11202010450VA patent/SG11202010450VA/en unknown
- 2019-06-20 CU CU2020000096A patent/CU20200096A7/es unknown
- 2019-06-20 MD MDE20210392T patent/MD3810602T2/ro unknown
- 2019-06-20 RS RS20231178A patent/RS64932B1/sr unknown
- 2019-06-20 IL IL279554A patent/IL279554B1/en unknown
- 2019-06-20 PE PE2020001917A patent/PE20210181A1/es unknown
- 2019-06-20 AU AU2019289888A patent/AU2019289888A1/en active Pending
- 2019-06-20 BR BR112020025869-5A patent/BR112020025869A2/pt unknown
- 2019-06-20 KR KR1020217001354A patent/KR20210022655A/ko unknown
- 2019-06-20 US US16/446,868 patent/US20200039945A1/en not_active Abandoned
- 2019-06-20 DK DK19734722.2T patent/DK3810602T3/da active
- 2019-06-20 UY UY0001038270A patent/UY38270A/es unknown
- 2019-06-20 MX MX2020012723A patent/MX2020012723A/es unknown
- 2019-06-20 LT LTEPPCT/EP2019/066337T patent/LT3810602T/lt unknown
- 2019-06-20 PT PT197347222T patent/PT3810602T/pt unknown
- 2019-06-20 TW TW108121417A patent/TWI826471B/zh active
- 2019-06-20 EP EP19734722.2A patent/EP3810602B1/en active Active
- 2019-06-20 CR CR20210032A patent/CR20210032A/es unknown
- 2019-06-20 ES ES19734722T patent/ES2967983T3/es active Active
- 2019-06-20 GE GEAP201915535A patent/GEP20227403B/en unknown
- 2019-06-20 EA EA202092451A patent/EA202092451A1/ru unknown
- 2019-06-20 EP EP23202715.1A patent/EP4335439A3/en active Pending
- 2019-06-20 FI FIEP19734722.2T patent/FI3810602T3/fi active
- 2019-06-20 HR HRP20231467TT patent/HRP20231467T1/hr unknown
- 2019-06-20 JP JP2020571368A patent/JP2021529738A/ja not_active Withdrawn
- 2019-06-20 CA CA3101238A patent/CA3101238A1/en active Pending
- 2019-06-20 HU HUE19734722A patent/HUE064744T2/hu unknown
- 2019-06-20 WO PCT/EP2019/066337 patent/WO2019243491A1/en active Application Filing
- 2019-06-20 MA MA52948A patent/MA52948B1/fr unknown
- 2019-06-20 PL PL19734722.2T patent/PL3810602T3/pl unknown
- 2019-06-20 CN CN201980041013.4A patent/CN112334466A/zh active Pending
- 2019-06-21 AR ARP190101711A patent/AR114972A1/es unknown
-
2020
- 2020-11-23 EC ECSENADI202075270A patent/ECSP20075270A/es unknown
- 2020-11-24 CO CONC2020/0014586A patent/CO2020014586A2/es unknown
- 2020-12-02 NI NI202000092A patent/NI202000092A/es unknown
- 2020-12-09 PH PH12020500673A patent/PH12020500673A1/en unknown
- 2020-12-11 CL CL2020003219A patent/CL2020003219A1/es unknown
- 2020-12-17 DO DO2020000249A patent/DOP2020000249A/es unknown
-
2021
- 2021-08-03 US US17/392,356 patent/US20220153710A1/en active Pending
-
2024
- 2024-07-05 JP JP2024108906A patent/JP2024133637A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8541588B2 (en) * | 2009-01-12 | 2013-09-24 | Pfizer Limited | Sulfonamide derivatives |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11492346B2 (en) | 2019-06-18 | 2022-11-08 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3810602B1 (en) | Compounds | |
US11911372B2 (en) | Compounds | |
EP3189042B1 (en) | Tetrahydroisoquinoline derived prmt5-inhibitors | |
US10005792B2 (en) | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | |
US10494376B2 (en) | Tetrahydroisoquinoline derived PRMT5-inhibitors | |
JP6180426B2 (ja) | パーキンソン病の処置のためのキナーゼlrrk2モジュレーターとしての2−(フェニル又はピリド−3−イル)アミノピリミジン誘導体 | |
US20230103791A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
US11434245B2 (en) | WNT pathway modulators | |
US20210380548A1 (en) | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | |
US20140315881A1 (en) | Compounds and methods | |
MX2008005717A (es) | Aminopirimidinas utiles como inhibidores de la cinasa. | |
US9266864B2 (en) | VEGFR3 inhibitors | |
OA19881A (en) | Compounds. | |
NZ769026A (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CTXT PTY LTD, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MONASH UNIVERSITY;REEL/FRAME:049777/0608 Effective date: 20190612 Owner name: MONASH UNIVERSITY, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAGIAKOS, H. RACHEL;MORROW, BENJAMIN JOSEPH;FOITZIK, RICHARD CHARLES;AND OTHERS;SIGNING DATES FROM 20190609 TO 20190618;REEL/FRAME:049777/0518 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |